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1. Summary 
 
Glioblastoma multiforme (GBM) is a highly lethal and incurable cancer of the central nervous system 
and current therapies are challenged by GBMs invasive growth and chemo-radioresistance. Ca2+-
permeable N-Methyl-D-aspartate receptors (NMDARs) are important for synaptic transmission of 
excitatory neurons and essentially regulate the plasticity of our brain via activation of several NMDAR-
dependent signaling pathways. However, NMDARs have been shown to contribute to GBMs 
malignancy by promoting growth, survival and migration. Although the impact of NMDARs on GBM 
has been clearly demonstrated, the particular signaling pathways used by GBM are poorly known. The 
identification of the NMDAR signaling pathways used by GBM cells might therefore help to develop 
NMDAR-targeted cancer therapies which highly impact GBM cells but do not disrupt synaptic 
transmission in neurons. 
The NMDAR-dependent expression of early-response genes (ERGs) upon neuronal activity is essential 
for synaptic plasticity and the formation of long term memory. The expression of ERGs depends on 
NMDAR-induced DNA-double strand breaks (DSBs) in the transcriptional start site of these genes. 
Some neuronal ERGs encode for proto-oncogenes like cFos, suggesting that GBM cells might hijack 
NMDAR signaling pathways to promote proto-oncogenes expression. 
In order to investigate the impact of NMDAR-dependent ERG expression in GBM cells we intended to 
identify the hallmark of this NMDAR signaling pathway: The induction of NMDAR-dependent and 
Topoisomerase II β (Top2β) mediated DSBs in GBM cells. 
 
For this task we validated the expression of NMDARs and functional Ca2+ signaling in the LN229 GBM 
cell line, which revealed functional NMDAR signaling in LN229 cells. Immunofluorescence staining of 
the DSB marker 53BP1 showed that NMDARs activation induces DSBs in a subpopulation of GBM cells 
and that DSB induction depends on Top2β activity, which demonstrates an analogues NMDAR 
signaling pathway in GBM cells and neurons. 
Analysis of ERG expression revealed that NMDARs, the cAMP-responsive element binding transcription 
factor (CREB) and Top2β all contribute to the expression of cFos and the brain-derived neurotrophic 
factor (BDNF) in GBM cells. Inhibition of Top2β or NMDARs also impaired the expression of cFos in a 
primary GBM cell line. In a clonogenic survival assay knock-down of Top2β with siRNAs and inhibition 
of NMDARs decreased LN229 cells resistance to X-rays. Additionally, a newly discovered interplay of 
NMDAR signaling and IR damage response on the expression of BDNF and cFos might explain the high 
impact of NMDAR inhibition on radiosensitivity. Interestingly, inhibition of DNA-dependent protein 
kinase indicates that NMDAR-mediated transcription involves factors required in DSB repair, 
suggesting an important role for DNA repair in NMDAR-mediated transcriptional regulation. 
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The results presented in this work demonstrate a functional Top2β-dependent NMDAR signaling 
pathway in GBM cells. The radiosensitizing effect of Top2β and NMDAR inhibition reveals that 
targeting NMDAR-dependent and Top2β-mediated ERG expression might be a promising strategy for 
GBM therapy. 
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2. Zusammenfassung 
 
Glioblastoma multiforme (GBM) ist ein hoch letaler und unheilbarer Krebs des zentralen 
Nervensystems und sein invasives Wachstum und die Chemo-Radioresistenz stellen eine 
Herausforderung für die derzeitigen Therapien gegen GBM dar. Ca2+-permeable N-Methyl-D-Aspartat 
Rezeptoren (NMDARs) sind wichtig für die synaptische Übertragung von exzitatorischen Neuronen 
und regulieren im Wesentlichen die Plastizität unseres Gehirns durch Aktivierung verschiedener 
NMDAR-abhängiger Signalwege. Es hat sich jedoch gezeigt, dass NMDARs durch die Förderung von 
Wachstum, Überleben und Migration zur Malignität von GBM beitragen. Obwohl die Auswirkungen 
von NMDARs auf GBM eindeutig nachgewiesen wurden, sind die von GBM verwendeten Signalwege 
im Einzelnen nur wenig bekannt. Die Identifizierung der von GBM-Zellen genutzten NMDAR-
Signalwege, könnte daher dabei helfen NMDAR-gerichtete Krebstherapien zu entwickeln, welche stark 
auf GBM-Zellen wirken, aber die synaptische Übertragung von Neuronen nicht unterbrechen. 
Die NMDAR-abhängige Expression von early response genes (ERGs) in Folge von neuronaler Aktivität 
ist essentiell für die synaptische Plastizität und die Bildung von Langzeitgedächtnis. Die Expression von 
ERGs hängt von NMDAR-induzierten DNA-Doppelstrangbrüchen (DSBs) in der transkriptionellen 
Startstelle dieser Gene ab. Einige neuronale ERGs kodieren für Protoonkogene wie cFos, was darauf 
hindeutet, dass GBM-Zellen NMDAR Signalwege missbrauchen könnten, um die Expression von 
Protoonkogenen zu fördern. 
Um die Auswirkungen der NMDAR-abhängigen ERG-Expression in GBM-Zellen zu untersuchen, 
wollten wir das besondere Kennzeichen dieses NMDAR-Signalwegs identifizieren: Die Induktion von 
NMDAR-abhängigen und Topoisomerase II β (Top2β) vermittelten DSBs in GBM-Zellen. 
 
Für diese Aufgabe haben wir die Expression von NMDARs und funktionelle Ca2+-Signale in der LN229 
GBM-Zelllinie validiert, was eine funktionelle NMDAR-Signalweiterleitung in LN229-Zellen ergab. Die 
Immunfluoreszenzfärbung des DSB-Markers 53BP1 zeigte die Aktivierung von NMDARs-induzierten 
DSBs in einer Subpopulation von GBM-Zellen und dass die DSB Induktion von der Top2β-Aktivität 
abhängt, was einen analogen NMDAR-Signalweg in GBM-Zellen und Neuronen zeigt. 
Die Analyse der ERG-Expression ergab, dass NMDARs, cAMP-responsive element binding transcription 
factor (CREB) und Top2β alle zur Expression von cFos und dem brain-derived neurotrophic factor 
(BDNF) in GBM-Zellen beitragen. Die Inhibition von Top2β oder NMDARs beeinträchtigte auch die 
Expression von cFos in einer primären GBM-Zelllinie. In einem klonogenen Überlebensassay 
verringerte der Knock-down von Top2β mittels siRNAs und die Inhibition von NMDARs die Resistenz 
von LN229-Zellen gegen Röntgenstrahlen. Zusätzlich könnte ein neu entdecktes Zusammenspiel von 
NMDAR-Signalweiterleitung und IR-Schadensantwort auf die Expression von BDNF und cFos den 
hohen Einfluss der NMDAR-Inhibition auf die Strahlungsempfindlichkeit erklären. Interessanterweise 
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zeigt die Inhibition der DNA-abhängigen Proteinkinase, dass die NMDAR-vermittelte Transkription 
Faktoren beinhaltet, welche für die DSB-Reparatur erforderlich sind, was auf eine wichtige Rolle der 
DNA-Reparatur für die NMDAR-vermittelten Transkriptionsregulation hinweist. 
Die in dieser Arbeit vorgestellten Ergebnisse zeigen einen funktionellen Top2β-abhängigen NMDAR-
Signalweg in GBM-Zellen. Die radiosensibilisierende Wirkung durch die Inhibition von Top2β und 
NMDAR zeigt, dass die gezielte Inhibition der NMDAR-abhängigen und Top2β-vermittelten ERG-
Expression eine vielversprechende Strategie für die GBM-Therapie sein könnte. 
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3. Introduction 
 
3.1. Glioblastoma multiforme: Characteristics and treatment  
 
Glioblastoma multiforme (GBM) is an incurable cancer and the most common primary brain tumor in 
adults with an annual incidence rate of 3.2 per 100 000 in the USA. GBMs aggressive growth and poor 
prognosis classifies it as a WHO grade IV tumor [1, 2]. The median survival of GBM patients is 3 
months, which is prolonged to 14.6 months by the current standard therapy consisting of surgical 
resection, chemotherapy with temozolomide (TMZ) and radiotherapy. However, current therapies are 
not curative and less than 5% of the patients survive longer than 5 years [3, 4].  
Primary GBMs are marked by typical genetic alteration such as epidermal growth factor receptor 
(EGFR) overexpression, pleiotrophin mutation and loss of chromosome 10, whereas isocitrate 
dehydrogenase 1 (IDH1) mutations, tumor suppressor TP53 mutations and chromosome 19q loss are 
more common in secondary GBMs [2]. However, therapeutic targeting of pathways correlated with 
these typical mutations gave no striking progress for therapy by now [5-7]. Despite typical genetic 
alteration and resistances, GBM tumors are in fact highly heterogeneous. Surgical multisampling 
revealed several subclones within a single tumor. Single cell analysis demonstrated that subclones use 
different signaling pathways and have variable tumorigenety [8]. GBMs heterogeneity is based on 
different characteristics of subpopulations inside the tumor with variable expression patterns and 
resistances [8, 9], which makes GBM´s inhomogeneity a major challenge for therapeutic approaches. 
The failure to cure or at least control GBM growth is due to the tumors invasive growth as well as high 
chemo- and radioresistance [10-12]. High radioresistance is characteristic for GBM. During 
radiotherapy, GBMs are exposed to ionizing radiation (IR), which is capable to detach electrons form 
atoms or molecules and potentially damages all cellular structures of tumor cells. The main cytotoxic 
effect of IR depends on the induction of DNA damage or precisely DNA double-strand breaks (DSBs), 
which in high number induce apoptosis, necrosis or senescence [13]. In conventional GBM 
radiotherapy the tumor is irradiated with 60 Gy X-rays within 6 weeks applied in 2 Gy fractions, which 
improves the overall survival of GBM patients but is not curative [14]. GBMs resistance to IR is 
promoted by an improved DNA damage response. GBM cells show a high DNA repair capacity, 
induction of cell cycle checkpoints, which stop cell cycle progression for DNA damage repair as well as 
expression of anti-apoptotic factors [9, 10, 13, 15]. 
Additional to IR, chemotherapy with TMZ is used to treat GBM. The toxic effect of TMZ on cells 
depends on the alkylation of nucleobases during replication. The alkylation causes mismatch of DNA 
base pairs, which results in the formation of DSBs and eventually induces cell death [16]. However, 
GBM cells have been shown to express O6-methylguanine DNA methyltransferase (MGMT), a repair 
protein which mediates resistance towards TMZ [17]. In addition, ATP binding cassette transporters 
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actively clear chemotherapeutic drugs from the cytosol, further promoting chemoresistance in GBM 
cells [18]. 
Beside the strong chemo-and radioresistance GBM treatment is complicated by the typically high 
invasive growth of GBMs. Even radical resection fails to remove all tumor cells and remaining cells 
with high tumorigenicity cause fast recurrence of GBM tumors [3]. Because of their highly tumorigenic 
nature, such cells have been described as tumor initiating cells (TICs) [19, 20]. These TICs represent a 
subpopulation of cells which play a key role in new therapeutic strategies. Unfortunately, the highly 
invasive tumorigenic subpopulations of GBM cells exhibit especially high resistances towards radiation 
and chemotherapeutics [10, 21]. 
 
 
3.1.1. GBM heterogeneity and development  
 
The highly invasive and proliferating TICs can generate cancer cells with different properties and 
induce tumors which faithfully represent the phenotype of the initial tumor. The proliferation capacity 
of TICs and the ability to produce GBM cancer cells with different phenotypes led to the terminus of 
“glioma stem cells” (GSC) which are thought to primarily initiate GBM (Figure 1a) [19]. The most 
favored theory by now is, that GBM stem cells develop through malignant transformation of neural 
stem cells (NSCs) [19, 22]. In the adult brain, NSCs can be found in so called stem cells niches in the 
subventricular zone of the lateral ventricle and the subgranular zone of the dentate gyrus [23]. Inside 
these stem cell niches, NSCs have ability to self-renewal and differentiate which gives rise to 
progenitor cells. These progenitor cells leave the stem cell niche and differentiate into neurons, 
astrocytes or oligodendrocytes, the three primary cell types of the central nervous system (CNS) [23]. 
In mice, it has been shown, that NSCs which carry driver mutations of GBM radially migrate from NSC 
niches and produce malignant gliomas at distance brain regions [24]. Interestingly, GBM cells have 
been divided into subpopulations which exhibit expression patterns of neurons, astrocytes and 
oligodendrocytes [25, 26], including expression of typical marker proteins like oligodendrocyte marker 
O4 or astrocyte associated glial fibrillary acidic protein (GFAP) [10, 27].  
To study TICs in vitro, GBM samples can be dissociated and cultured under serum free conditions with 
the stem cell mitogens epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2). These 
culture conditions cause most GBM cells to die, but TICs keep proliferating and form non-adherent 
spheres, providing a cell culture model enriched in TICs [28]. Upon removal of stem cell mitogens, the 
sphere culture again produces GBM cells with different phenotypes (Figure 1b) [19]. This proposes 
that GSCs might have the capacity to “differentiate” into heterogeneous GBM cell types, which reflect a 
partial phenotype of normal brain cells and provide an explanation for the characteristic diversity of 
GBM tumors.  
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Figure 1: Hierarchical organization of GBM. (a) GBM tumors exhibit a subpopulation of self-renewing and dividing cells 
(yellow), who produce cancer cell with different phenotypes (green, red, purple), which lost the ability for self-renewal. The 
dividing subpopulation is highly tumorigenic. (b) Dissociated GBM samples form spheroids enriched in TICs when cultured with 
EGF and FGF2. When GBM spheres are dissociated they keep growing in sphere cultures. Upon growth factor depletion GBM 
spheres again produce cancer cells with different phenotypes (adopted from Vescovi et al  [19]). 
 
 
3.1.2.  The role of glutamate in GBM 
 
A specific characteristic of GBM is the active secretion of glutamate (Glu) which accumulates to high 
concentration (~250 µM) in the tumors vicinity [29-31]. Glu is a metabolite which is educt and 
product of many reactions throughout the body, but essentially Glu is the most common excitatory 
neurotransmitter in the mammalian brain [32]. The physiological activation of glutamate receptors 
(GluRs) by Glu is besides neuronal signal transmission a key signal for synapses modulation and 
therefore needed for fundamental cognitive functions such as memory and learning [33, 34]. 
Pathological activation of GluR in GBM patients interferes normal GluRs signaling and can additionally 
induce seizures, which cause significant morbidity for patients [35]. On the cellular level, persistent 
and high concentrations of Glu secreted by GBM tumors induce excitotoxicity in nearby neurons as a 
result of prolonged GluR activation, causing neuronal tissue to die and providing accruing space for 
GBM growth [30]. 
The excitotoxic Glu release of the tumor is mainly mediated via system X-c, a cystine/glutamate 
exchanger, highly expressed in GBM cells [36, 37]. Additionally, GBM cells have low expression of the 
excitatory amino acid transporters (EAAT) and especially EAAT2, which is responsible for Glu uptake 
in the brain for example by astrocytes. It has been demonstrated that several primary GBMs as well as 
GBM cell lines show low expression of EAAT2 and consequently highly decreased Glu uptake 
compared to astrocytes [36, 38]. This high Glu secretion- low Glu uptake mechanism of GBMs further 
increases the accumulation of Glu in the tumor vicinity. 
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The cystine, which is transported into the cell upon Glu release by system X-c, is used by GBM cells to 
synthesize glutathione (GSH), a radical scavenger which has been shown to promote growth of GBM 
cells [39]. The physiological role of cystine in cell growth raised the question, if Glu release has a 
direct effect on GBM cells or is a byproduct of cystine uptake. The specific effect of Glu on GBMs was 
shown by Lyons et al. in 2007. They used sulfasalazine (SAS) to inhibit the system X-c in GBM cells, 
which decreased secretion of Glu in a dose-dependent manner. It has been demonstrated that SAS 
treatment and inhibition of GluRs comparably reduce growth and invasion of GBM cells in vitro, 
indicating a direct effect of Glu on GBM signaling and migration. [39, 40]. Hence, GBM-mediated Glu 
release not only acts on surrounding neurons but also on GBM in an autocrine way. 
 
 
Glu operates via Ca2+ conducting GluRs in GBM cells 
 
As known from neurons glutamatergic signaling can be transmitted via GluRs. Dependent on the 
intracellular signal transduction GluRs are divided into two types: Metabotropic glutamate receptors 
(mGluRs) and ionotropic glutamate receptors (iGluRs), which are both expressed in GBM cells [41]. 
However, especially Ca2+ signaling has been shown to be important in GBM cells [42] and Ca2+ 
conducting iGluRs are known to promote proliferation and migration in neuronal cells [43]. 
Accordingly, it was supposed, that Glu-mediated growth and migration in GBM depends on the 
activation of Ca2+ conducting iGluRs [40]. 
iGluRs are divided into three groups which are defined by their specific agonist: kainate-receptors, α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and N-Methyl-D-aspartate-
receptors (NMDARs). The role of kainate-receptors on GBM has been neglected, since kainat-receptors 
typically have very limited permeability for Ca2+ [44]. AMPARs show a similar low Ca2+ permeability 
in neurons. The high expression of the AMPAR subunit GluA2, which assembles to Ca2+-impermeable 
AMPARs, causes the low Ca2+-permeability of neuronal AMPARs. Interestingly, GBM cells have been 
reported to lack the AMPAR subunit GluA2, resulting in the expression of Ca2+ permeable AMPARs in 
GBM [40, 45] and blockage of AMPARs slowed the migration of GBM cells [46].  
Anyhow, the iGluRs with the highest conductance for Ca2+ are NMDARs. In contrast to fast 
desensitizing AMPARs, NMDARs allow a prolonged influx of Ca2+ upon activation, which is known to 
be essential for downstream genomic regulation in neurons [43]. The expression of NMDARs has been 
reported not only in GBM cells but in many other cancers as well [47-54], indicating that NMDAR 
expression may be implicated in the signaling of various cancers types. 
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3.2. N-Methyl-D-aspartate-receptor: Structure and function 
 
NMDARs play a key role in synaptic transmission and therefore are highly expressed throughout the 
brain. All known NMDARs are heterotetrameric assemblies, which are composed of two essential 
GluN1 subunits and varying contributions of two GluN2A-D subunits or GluN3A-B subunits [43, 44, 
55]. In the brain, GluN1 mostly assembles with GluN2A or GluN2B. The assembled channel pore is 
selective for cations with high permeability for Ca2+ and lower permeability for Na+ and K+. An unique 
property which distinguishes NMDARs from other iGluRs is that channel opening needs binding of two 
different ligands [56]. The fist ligand is glycine (Gly) or D-serine, which binds to the GluN1 subunit 
while the second ligand Glu binds to GluN2 subunits [43]. In order to activate synaptic NMDARs the 
transient release of Glu is sufficient, while the extracellular Gly concentration is constantly high 
enough to activate NMDARs [43, 57].  
Each NMDAR subunit consists of four domains: The extracellular amino-terminal domain (ATD) plays 
an important role in receptor assembly and binds allosteric modulators like ifenprodil. The agonist 
binding domain (ABD) consists of two polypeptide sequences (S1 and S2 Figure 2b). These sequences 
form two lobes (upper lobe D1, lower lobe D2 Figure 2b) with a cleft in between, in which the ligand 
binds. The transmembrane domain (TMD) consists of three transmembrane helices (M1, M3 and M4) 
and the reentrance loop (M2). They form the channel pore which is the target of channel blockers like 
MK801. The intracellular carboxyl-terminal domain (CTD) binds scaffold and signaling proteins which 
are associated with NMDARs, like PSD-95 and calmodulin [43]. In addition, the CTD is subject to 
phosphorylation modulating NMDARs trafficking and currents [58]. 
GluN2A/B subunits are typical for synaptic NMDARs in the forebrain with slightly different properties 
than GluN2C/D containing NMDARs. GluN2A/B ligand affinity, for example, is relatively low with a 
concentration for half maximal activation (EC50) of ~2 µM Glu [59] while GluN2C/D have a higher 
affinity for Glu but a lower open probability. NMDARs containing GluN2B and especially GluN2A have 
a higher open probability, resulting in an increased Ca2+ conductance [43]. These GluN2A/B 
containing receptors also show the highest sensitivity for Mg2+ blockage [60], which is a characteristic 
property of NMDARs. 
At the resting membrane potential of neurons (~-70 mV), the channel pore of NMDARs is blocked by 
Mg2+. This block relieves as the membrane depolarizes and can be removed by depolarization of 
membrane potential to ~-20 mV. To overcome this ion-block, NMDARs are expressed together with 
AMPARs at synapses. Upon presynaptic Glu release, AMPAR activation first depolarizes the membrane, 
which resolves the Mg2+ block in NMDARs. Then NMDARs channel open, allowing Ca2+ to enter the 
cell [43]. The highly increased intracellular Ca2+ concentration is a second messenger signal for further 
neuronal signaling as gene activation and subsequently physiological adaptions. In neurons, NMDAR-
mediated Ca2+ influx regulates a vast number of genes [61], promoting survival, migration, 
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proliferation and synaptic plasticity [34, 43, 62-64], which makes NMDAR activation indispensable for 
neurons. 
 
Figure 2: Assembly and structure of NMDARs. (a) NMDARs are tetramers classically consisting of two GluN1 subunits, which 
bind glycine and D-serine (blue) and two GluN2 subunits, which bind Glu (orange). Both agonists must bind for channel 
opening, allowing the channel pore to conduct cations like Ca2+, Na+ and K+. (b) NMDAR subunits have four major domains: 
The amino-terminal domain (green), which binds allosteric modulators of the channel like ifenprodil. The agonist binding 
domain (blue) consists of the polypeptide sequence between ATD and M1 transmembrane domain (upper lobe, S1) and the 
polypeptide sequence between M3 and M4 transmembrane domains (lower lobe, S2). The agonist-binding site is located in 
the cleft between the two lobes. The transmembrane domain (orange) builds the channel pore through the membrane and 
consists of three transmembrane helices (M1, M2, and M4) and a membrane reentrance loop (M2). The channel pore is the 
target of channel blockers like MK801. The intracellular carboxyl-terminal domain binds scaffold and signaling proteins (Figure 
adopted from Hansen et al. [43]). 
 
 
3.2.1. The role of NMDARs in cancer 
 
The function of NMDARs in synaptic transmission has been investigated for a long time, but NMDAR 
expression is not restricted to neurons. In fact, NMDAR can be found in cells and tissues from all germ 
layers including pancreatic islet cells, bone cells, epithelial cells, keratinocytes, the urogenital tract and 
the cardiovascular system [65-70], demonstrating the importance of NMDAR signaling beyond 
synaptic transmission. Based on these findings, it is not surprising that primary brain tumors are not 
the only cancers which express NMDARs. A broad variety of cancer types have been reported to 
express NMDARs [47, 48]. In addition, Glu secretion has been demonstrated in other tumors beside 
GBM [31, 50, 71], providing the base for a functional signaling circuit. 
In 2001, Rzeski et al. reported that MK801, a specific NMDAR inhibitor, limits the growth of several 
human cancer cell lines including neuroblastoma, thyroid carcinoma, colon adenocarcinoma, breast 
carcinoma and lung carcinoma in vitro and thus suggested functional NMDAR expression in many 
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cancers [72]. Subsequent works confirmed the expression of NMDARs in several cancer cell lines as 
well the anti-proliferative effect of NMDAR inhibitors [49, 52-54, 73]. Additionally, the potential 
therapeutic value of NMDAR inhibition was demonstrated when the in vivo growth of tumor xenografts 
in mice was limited for small-cell lung cancer and breast cancer cell lines upon MK801 treatment [52, 
53]. Immunohistological staining proposed a correlation of NMDAR expression and high tumor grade 
in breast and prostate cancer [49, 53] as well as in glioma [50], suggesting that NMDAR expression 
might support tumor malignancy.  
qPCR profiling of 13 cancer cell lines revealed that all tested cell lines expressed mRNAs coding for 
NMDAR subunits and only three cell lines lacked expression of the essential GluN1. NMDAR subunits 
were differently expressed in the cell lines. While GluN2B and GluN2C subunits were transcribed in all 
cell lines the GluN2A was missing in a neuroblastoma (SK-NA-S) and thyroid carcinoma (FTC 238) 
[47]. The varying NMDAR composition might define the role of NMDARs in cancer cells. For example, 
increased proliferation upon NMDAR activation has been reported in the GluN2B deficient gastric 
cancer cell line MKN45. The authors could show the ability of GluN2A containing NMDARs to promote 
proliferation by knocking down GluN2A with siRNA [54]. Furthermore, GluN2B is thought to be a 
tumor suppressor which is epigenetically downregulated in human esophageal cancer [74]. On the 
other hand, the GluN2B specific antagonist ifenprodil was equally potent to reduce the viability of 
small-cell lung cancer cells (H345 and H82) as MK801, which demonstrates the impact of the GluN2B 
subunit on proliferation in the tested cell lines [52]. Ifenprodil also decreased the proliferation and 
migration of LN229 GBM cells [73], which is in line with the observations of Li and Hanahan, who 
claimed that GluN2B promotes migration and invasion in several cancers including GBM. Invasion of 
tumor cells into healthy tissue displays a major problem for therapies. GBM patients with tumors 
expressing the GluN2B subunit and consequently higher invasiveness indeed had a significantly 
decreased survival [50, 75]. The bivalent role of GluN2B in different cancers shows that NMDAR 
subunit composition does not solely define the effect of NMDAR activation in cancer and that 
cancerous NMDAR signaling is complex. 
The fact that NMDAR signaling has various effects in different cells is also demonstrated by the 
paradox role of Glu in GBM tumors. On the one hand, activation of NMDARs with pathological 
concentration of Glu leads to epilepsy and neuronal cell death in GBM patients via the activation of 
NMDARs and AMPARs. At the same time, Glu activates NMDARs in GBM cells and promotes survival, 
proliferation and migration (Figure 3) [50, 73, 76]. This shows that NMDARs do not have a distinct 
function but can promote opposing cellular effects. 
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Figure 3: Pathological release of Glu by GBM effects neurons and GBM cells via NMDARs. GBM cells secrete Glu via the 
cystine/glutamate exchanger system X-c. Cystine is used for glutathione (GSH) synthesis and Glu accumulates in the 
extracellular space, because reuptake of Glu via EAAT transporters is downregulated in GBM cells. Glu acts autocrine and 
paracrine on GBM cells and neurons. Uncontrolled activation of NMDARs and AMPARs in neurons leads to epilepsy and 
neuronal cell death through excitotoxicity. NMDAR signaling promotes proliferation, survival and migration/invasion in GBM 
cells upon NMDAR activation (Figure adapted and changed from Lefranc et al. 2018 [76]).  
 
 
3.2.2. NMDAR signaling in neurons and cancer 
 
The effect of NMDAR activation depends on intracellular signaling 
 
NMDAR-mediated Ca2+-influx can induce both, neuronal survival and death. While the activity of 
synaptic NMDARs is known to promote survival, the activation of extrasynaptic NMDARs primarily 
promotes apoptosis, indicating that the receptors localization defines the effect of NMDAR activation. 
Ca2+-induced apoptosis in neurons depends on the cytosolic concentration of Ca2+ [77]. Extensive 
accumulation of cytosolic Ca2+ leads to the depolarization of the mitochondrial membrane due to 
Ca2+-uptake into the mitochondria. This Ca2+ overload induces swelling of mitochondria which results 
in rupture of the outer membrane and release of apoptotic factors like cytochrome c and apoptosis 
inducing factor (AIF) [78].  
The induction of apoptosis is a direct result of high Ca2+-influx upon NMDAR activation, while 
activation of other signaling pathways, like the ERK1/2 or CaMKIV pathway, depend on the connection 
of receptor and intracellular proteins [79]. At the synapse, NMDARs are bound to scaffold proteins of 
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the postsynaptic density, including membrane-associated guanylate kinases (MAGUK) like PSD-95 and 
guanylate kinase-associated protein (GKAP) which are known to bind intracellular signal transducing 
proteins [80, 81]. The proximity of NMDARs and signaling proteins then allows activation of 
preferential signaling pathways and also effective buffering of intracellular Ca2+ [79]. 
In newborn rats, the GluN2B subunit is highly expressed in the forebrain. During the first weeks of life, 
the expression of the GluN2B slowly declines, while the expression of the GluN2A subunit increases, 
indicating that GluN2B expression is especially important for brain development [82, 83]. The 
observation led to the propose that GluN2A subunits mainly mediate synaptic NMDAR signaling in 
mature neurons, while GluN2B subunits were thought to promote extrasynaptic signaling [82, 84]. 
Anyhow, GluN2A and GluN2B are both located at synapses and therefore contribute to synaptic 
signaling in neurons, promoting survival and synaptic plasticity [83, 85]. 
Neuronal survival upon synaptic NMDARs activation is mainly mediated by cAMP response element-
binding protein (CREB). CREB activation in turn is known to be regulated by two different signaling 
pathways upon NMDAR activation: The Ca2+/calmodulin kinase IV (CaMKIV) pathway and the 
extracellular signal-regulated kinases (ERK) pathway. CaMKIV is activated upon binding of 
Ca2+/calmodulin and phosphorylates CREB at Ser133 and also the CREB cofactor CREB-binding 
protein (CBP). Both phosphorylations lead to the activation of CREB, allowing it to promote 
transcription (Figure 4Aa/Ac) [79]. CaMKIV-mediated CREB activation is a fast but short-lasting 
process and mediates fast response to NMDAR signaling. Longer lasting activation of CREB is mediated 
by the ERK1/2 [86]. In order to promote ERK1/2-dependent CREB phosphorylation, Ca2+/calmodulin 
activates the Ras-specific GDP/GTP exchange factor RasGRF1 which activates Ras. Activated Ras-GTP 
binds to Raf which triggers downstream kinases, resulting in the activation of ERK1/2 (Figure 4Ab). 
Additionally, Ca2+/calmodulin activates calcineurin, a phosphatase which dephosphorylates transducer 
of regulated CREB activity (TORC). The dephosphorylated form of TORC is imported into the nucleus 
where assists CREB-dependent gene regulation (Figure 4Ad) [79].  
Activation of extrasynaptic NMDARs in turn hinders CREB activation by inhibiting ERK1/2 (Figure 
4Ae). In addition, extrasynaptic NMDARs mediate dephosphorylation of CREB via the juxtasynaptic 
attractor of caldendrin on dendritic boutons protein (Jacob), which is translocated into the nucleus 
upon activation of extrasynaptic NMDARs (Figure 4Af) [79].  
NMDAR-mediated survival not only depends on the expression of survival factor but also on the 
inhibition of apoptotic factors. In this case, Ca2+/calmodulin activates phosphoinositide-3-kinase 
(PI3K) [87] which subsequently results in the phosphorylation of Akt. Then Akt phosphorylates factor 
forkhead box protein O 1 and 3 (FOXO1/3), which triggers the transcription of apoptotic factors like 
Bim, Fasl and Txnip. Upon phosphorylation FOXO1/3 is translocated into the cytoplasm which disrupts 
its activity. Contrary, activation of extrasynaptic NMDARs mediates the nuclear import of FOXO1/3 
(Figure 4Bb), which in turn can be inhibited by synaptic NMDARs (Figure 4Bc) [79]. Additionally, 
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Akt has been reported to activate CREB as well, which further emphasizes the central role of CREB 
activation for NMDAR-mediated survival in neurons [88]. 
Taken together NMDAR activation is an important initiating signal of varying cellular pathways 
depending on the intracellular signaling in neurons. 
 
 
Figure 4: Opposing effects of synaptic and extrasynaptic NMDARs via differential signaling. (A) Activity of synaptic NMDARs 
leads to the activation of CaMKIV and ERK1/2, which both phosphorylate CREB at Ser133 (Aa/Ab). CaMKIV also 
phosphorylates CBP, a cofactor of CREB, at Ser301 (Ac). Both phosphorylations activate CREB which initiates the transcription 
of pro-survival genes. Additionally, Ca2+-influx upon activation of synaptic NMDARs mediates the nuclear transport of TORC 
via dephosphorylation by calcineurin (Ad), which is an important step in CREB activation. Activation of extrasynaptic NMDARs 
inhibits ERK1/2 (Ae) and mediates the nuclear translocation of Jacob (Af), which promotes CREB dephosphorylation. (B) 
Synaptic NMDARs can activate the PI3K/Akt pathway, which induces the export of FOXO1/3 via phosphorylation (Ba). FOXO 
promotes the transcription of pro-apoptotic factors like Foxo1, Txnip, Bim and Fasl. Activation of extrasynaptic NMDARs 
mediates the nuclear import of FOXO1/3 (Bb), which can be inhibited by synaptic NMDAR activity (Bc) (adopted form 
Hardingham and Bading 2010 [79]). 
 
 
Cancer cells use neuronal NMDAR signaling pathways 
 
Compared to neurons, NMDAR signaling pathways in cancer cells are less well investigated. In one 
case, Li et al. could show that NMDAR-mediated invasion of the murine pancreatic neuroendocrine 
tumor cell line bTC-B6 depends on the expression of the synaptic protein GKAP. They revealed that 
GKAP high expressing cancer cell lines showed increased invasion and increased sensitivity to the 
NMDA blocker MK801. They further demonstrated that GKAP knock down decreased the response of 
bTC-B6 cells to NMDA in a fluorescent calcium indicator assay, indicating that expression of synaptic 
proteins is important for NMDAR signaling in cancer cells [75]. 
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Other authors reported that CREB is involved in NMDAR-mediated signaling in cancer cells. Previous 
results from our workgroup could demonstrate that NMDAR-expressing LN229 GBM cells show 
increased CREB phosphorylation upon Glu treatment [73]. In lung adenocarcinoma cells (A549), 
blockage of NMDARs with MK801 inhibits the phosphorylation of CREB at Ser133. Inhibition of 
NMDARs also decreased the phosphorylated form of MEK and ERK but not CaMKII and Akt, 
demonstrating that CREB activation is mediated by the ERK pathway in A549 cells [89]. Li and 
Hanahan demonstrated that MK801 treatment reduces the amount of phosphorylated CREB in murine 
βTC-3 cancer cells as well. They found that NMDAR signaling is propagated via the ERK and CaMKII 
signaling pathways and emphasized the dominant of the GluN2B subunit [50]. The fact that CaMKII 
binds to the GluN2B subunit [90] and the role of GluN2B and CaMKII in the migration of several 
cancers and neuros suggest that NMDAR promoted migration might depend on GluN2B-mediated 
activation of CaMKII [50, 63, 91-93]. 
Although the number of studies is limited, it has been clearly shown that several cancers use NMDAR-
dependent CREB activation to promote survival and growth [50, 89]. In addition, high CREB 
expression was observed in many cancers including melanoma, breast cancer and glioblastoma, where 
it has been correlated with cancer survival and poor prognosis [94-97]. A prominent gene, which is 
typically regulated upon NMDAR activation and CREB phosphorylation, is cFos. cFos is a proto-
oncogene, which is highly expressed in many cancers where it promotes tumor progression and 
radioresistance [98-102] and which is expressed upon NMDAR activation in the A549 cancer cell line 
[89]. 
The role of CREB and NMDARs in varying cancer types made both proteins to proposed targets for 
cancer therapy [48, 94], suggesting that NMDAR-mediated CREB signaling might play a regulative role 
in the progress of different cancer types. 
 
 
3.3. The induction of DSBs is needed for NMDAR-dependent and CREB-mediated gene 
expression 
 
In neurons, activation of synaptic NMDARs leads to the expression of early response genes (ERGs). 
ERGs are rapidly expressed dependent on CREB activation and encode for transcription factors 
including cFos, cJun and Egr1 [103, 104]. The expression of ERGs is mediated by the DNA-dependent 
RNA polymerase II (PolII) and the expression level peaks around 30 min after stimulus and then 
declines [105]. In 2010, Kim et al. could show that CREB and PolII are both bound to the transcription 
start site (TSS) of early response genes before stimulus induction. Their results indicate that the pre-
binding of transcription factor and RNA polymerase enables a faster start of transcription upon 
activation of synaptic receptors. Furthermore, they showed that CBP is not localized at TSS in 
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unstimulated cells, proposing that the binding of CBP to CREB is the initiating step of ERG expression 
[106].  
In 2015, Madabhushi et al. expanded the mechanism of NMDAR-dependent and CREB-mediated 
expression of early response genes. They noticed that the expression of ERGs increased and persisted 
in active neurons when topoisomerase II (Top2) was inhibited with etoposide [104]. Top2 unwinds 
DNA by inducing a single DSB followed by subsequent religation of the DNA damage, and therefore 
has an important role in removing topological tension inside the DNA during replication and 
transcription [107]. Etoposide inhibits Top2-mediated religation, inducing persisting DSBs at sites of 
Top2 activity. In subsequent experiments Madabhushi and colleges found that topoisomerase II β 
(Top2β) induces DSBs inside the TSS of ERGs upon NMDAR activation, which are essential to start 
PolII-dependent transcription of ERGs. The induction of DSBs at the specific TSS even was sufficient to 
induce gene transcription without activation of NMDARs, indicating that Top2β-mediated induction of 
DSBs is a key step in NMDAR-mediated gene regulation (see Figure 5). 
 
 
Figure 5: Top2β-mediated DSBs govern NMDAR and CREB-dependent gene transcription. In absence of neuronal activity, 
CREB and serum response factor (SRF) are bound to promoter and enhancer region of ERGs. The transcription activator ELK1 
as well as PolII are also pre-bound to the promoter. The transcriptional repressor CTCF binds close the TSS and holds the 
expression of EGRs inactive together with histone deacetylase 2 (HDAC), which is bound to the promoter. Top2β binds close 
the CTCF binding sites. Upon neuronal activity, histone deacetylase 2 is released by activated calcineurin activity and increased 
Top2β activity induces a DSB into the promoter region of the ERG. This DSB relieves topological tension of the DNA, which 
enables enhancer-promoter interaction, allowing the pausing PolII to start gene transcription (Adopted from Madabhushi et 
al. [104]). 
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Furthermore it has been shown that inhibition of non-homologues end joining (NHEJ), which is the 
main DSB repair mechanism, led to prolonged expression of ERGs upon NMDAR activation. This 
indicates that ERG inactivation relies on the repair of regulatory DSBs by NHEJ and not by Top2β 
[104]. 
Based on these findings they extended the model of NMDAR-mediated gene regulation of ERGs in 
neurons described by West and Greenberg [108]. Without stimulation CREB and several regulatory 
factors are already bound to the TSS and PolII rests at the promoter. Top2β is bound near the 
transcriptional repressor CTCF. Upon NMDAR stimulation, Top2β get activated and induces DSBs into 
the TSS of ERGs including cFos, Npas4 and EGR, but not in the TSS of late-response genes like BDNF 
and Homer1. This reduces topological constrains inside the DNA and allows promoter-enhancer 
interaction, which allows the resting PolII to start gene transcription (Figure 5) [104]. 
 
 
3.3.1. Topoisomerase II β: Function and role in transcription  
 
DNA topoisomerases are enzymes that solve topological problems inside the DNA which result from 
strand separation during replication and transcription. The genome of human cells encodes for six 
different topoisomerases called Top1, Top1mt, Top2α, Top2β, Top3α and Top3β. Topoisomerases of 
subgroup one and three are type I topoisomerases, which means they resolve supercoiled DNA 
structure through induction of a single-strand DNA break, unwinding of DNA and subsequent 
religation. The activity of type I topoisomerases is essential during replicational and transcriptional 
elongation [109].  
Top2α and Top2β are type II topoisomerases. Although, both types of topoisomerases use transient 
covalent linkage of a Tyr residue to the phosphate backbone of DNA in order to unwind the DNA, type 
II topoisomerases induces breakage of both DNA strands within four base pairs, resulting in a DSB. The 
complete break of DNA allows the passage of one DNA strand through another, which is needed to 
solve DNA knots and catenanes [109]. For this, Top2 homodimers bind two DNA strands, called G and 
T segment. The G segment is cleaved and upon hydrolysis of ATP the T segment is transported through 
the break. ATP is also needed to religate the G segment. Finally, dissociation of ADP allows opening of 
the C-terminal and the ATPase domain, which releases the T segment from C-terminal domain and 
Top2 from the DNA (Figure 6) [110]. 
Compounds which inhibit a specific step of Top2´s catalytic cycle are broadly used in cancer therapy 
[107, 110]. Most important for cancer therapy are Top2 inhibitors which result in the induction of 
DSBs, so called Top2 poisons [111-113]. Induction of DSBs by Top2 poisons promotes apoptosis or 
senescence in cancer cell but exposure to Top2 poisons has been associated with young age leukemia 
[114] and poisoning of Top2β with etoposide increased the incidence of melanoma in mice [115]. 
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Interestingly, Top2β activity upon androgen-receptor activation has also been correlated with genomic 
rearrangements, which lead to the development of prostate cancer [116]. In this line, Top2β activity 
was supposed to be both: oncogenic force and potential therapeutic target in cancer [117]. 
Top2α and Top2β have different physiological roles. The expression of Top2α increases during S/G2-
phase and Top2α activity is especially important during chromosome segregation and chromosome 
condensation, while Top2β shows no cell cycle specific expression and is especially needed during 
transcription [109, 118]. 
 
 
Figure 6: Catalytic cycle and inhibitors of Top2 enzymes. ATPase domain is shown in light blue and the DNA-binding and 
cleavage core domain and the C-terminal domain are dark blue. (1) First, the core domain binds one DNA double strand (G 
segment; red) and the ATPase domain binds a second DNA double strand (T segment; green). (2) Two ATP molecules bind to 
the ATPase domain which forms a closed clamp around the T segment. (3) The cleavage of the G segment is Mg2+-dependent 
and can be inhibited with merbarone. (4) Hydrolysis of the first ATP supports the passage of T segment through the G 
segment. This step can be inhibited with etoposide, which traps the enzyme with a broken DNA double strand. (5) Hydrolysis 
of the second ATP is needed for religation of the G segment. (6) Dissociation of ADP enables the release of the T segment 
through the C-Terminal gate. This step can be inhibited by ICRF-193, which traps Top2 in an inactive state. (7) Top2 can 
dissociate from the G segment (adopted and modified from Larsen et al. [110]). 
 
Interestingly, Top2β knock out mice have no morphological abnormalities in major organs but die 
perinatal [119]. qPCR revealed that in mice only a small number of genes (1-4%) were affected by 
Top2β knock-out during early embryonal development, indicating that Top2β is not generally needed 
for transcription [120]. Anyhow, Top2β deficient mice show abnormal neural and neuromuscular 
development, indicated by motor neurons which fail to innervate the diaphragm muscle and missing 
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sensory projections in the spinal cord as well as mainly suppressed transcription of late developmental 
genes [119, 120]. In addition, brain specific knock down of Top2β caused abnormal lamination of the 
cerebral cortex and decreased migration of neurons [121], suggesting that Top2β activity is required 
for the transcription of specific genes. A mechanism for specific gene regulation by Top2β in neurons, 
as described in Figure 5, was reported later. Here Top2β induces persistent DSBs, which are not 
religated by Top2β itself [104].  
Nevertheless, the induction of regulatory DSBs by Top2β was not primarily discovered in neurons, but 
was reported earlier in MCF-7 breast cancer cells. Here, Top2β inflicted DSBs are required for the 
expression of estrogen receptor α regulated genes, which was confirmed by another groups [116, 122, 
123]. In addition, glucocorticoid receptor transcriptional activation has been shown to be dependent 
on Top2β activity as well [124]. 
By now it is unknown how Top2β activity is regulated in context of transcriptional activation. Several 
proteins which are part of the DNA damage response are associated with Top2β, including 
poly(ADPribose)polymerase 1 (PARP1), DNA-dependent protein kinase (DNA-PK) and KU70 [122] as 
well as the serine/threonine kinase ATM [123]. Inhibition of DNA-PK and ATM decreased the number 
of DNA breaks upon activation of estrogen receptor α [123], indicating a role of these proteins in the 
induction of DSBs. But the number of Top2β-induced DSBs has also been reported to be increased 
upon DNA-PK inhibition, indicating a role in repair [104]. Ribosylation of Top2β by PARP1 decreases 
its catalytic activity [125] and might therefore play a role in Top2β inactivation [126]. On the other 
hand, PARP1 deficient cells showed decreased activity and expression of Top2β but not Top2α [127]. 
In addition, Top2 activity is modulated upon phosphorylation, for example by Casein kinase II [128], 
but Top2 is phosphorylated by many kinases among different species, including protein kinase A and 
C, ERK1/2 and CaMK [118]. Taken together, Top2β is involved in the signal transduction pathways of 
extracellular stimuli and induces regulatory DSBs, which promote transcription but also display a risk 
for genomic integrity [117].  
 
 
3.4. Aim of study 
 
Activation of neuronal NMDARs is multifunctional. NMDAR-mediated Ca2+ transients regulate a vast 
variety of genes in neurons which are essential for synaptic plasticity and memory formation and can 
also promote migration, survival and death [34, 61-63, 79, 129]. The effect of NMDAR activation 
depends on the expression of intracellular signaling proteins and the coupling of these proteins to the 
receptor, which allows NMDARs to activate distinct signaling pathways [75, 79]. GBM and other 
cancer cells hijack NMDAR signaling pathways to drive tumor malignancy by increasing their growth, 
survival and invasiveness [30, 49, 50, 52, 53, 73]. However, the essential role of NMDARs for neuronal 
activity limits the benefit of direct NMDAR inhibition in cancer therapy, since the general inhibition of 
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NMDARs by potent drugs induces severe side effects, including loss of memory and psychosis [130]. 
Inhibition of particular NMDAR signaling pathways or specific NMDAR subunits, which contribute to 
NMDAR-mediated malignancy in cancer cells, might be a possible way to target NMDARs in cancer 
therapy without disrupting synaptic transmission. However, the particular signaling pathways used by 
cancer cells are poorly investigated. 
The finding, that NMDAR activity in cancer cells mediates Ca2+-dependent activation of CaMKII/IV and 
ERK1/2 and phosphorylation of CREB, suggests similar NMDAR signaling in cancer cells and neurons 
[50, 73, 89]. In neurons, NMDARs promote strong expression of several ERGs by the induction of 
Top2β-mediated DSBs [104]. ERGs regulated by Top2β-induced DSBs include proto-oncogenes like 
cFos [100, 104, 105], suggesting that cancer cells might use this particular NMDAR signaling pathway 
to promote their own survival and growth.  
Highly malignant GBM cells use NMDAR activation to promote growth, survival and invasion, which 
display severe obstructions for successful therapies [50, 73, 75, 131]. In order to identify potential 
therapeutic targets for GBM therapy inside NMDAR signaling pathways this study aims to investigate 
the impact of Top2β-dependent NMDAR signaling on GBM cells and therefore analyzed: i) The 
expression of NMDARs and functional Ca2+ signaling in the GBM cell line LN229. ii) NMDAR-
dependent induction of DSBs, the expression of the ERG cFos and subsequent expression of BDNF, in 
special respect of the contribution of GluN2B containing NMDARs in GBM cell lines and primary GBM 
cells. iii) And the therapeutic implications of Top2β-dependent NMDAR signaling in GBM cells upon 
irradiation with X-rays.  
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4. Material and Methods 
 
4.1. Antibodies 
 
Table 1: Primary antibodies 
Antibody Host Clone number; Manufacturer  
Anti-GluN1 rabbit D65B7; Cell Signaling (Danvers, U.S.A) 
Anti-GluN2A mouse N327A/38; Abcam (Cambridge, U.K) 
Anti-GluN2B mouse S59-20; Stress Marq (Victoria, Canada) 
Anti-Top2β mouse A-12; Santa Cruz (Dallas, U.S.A) 
Anti-53BP1 rabbit H-300; Santa Cruz 
Anti-cFos rabbit PA1318; BosterBio (Pleasanton, U.S.A) 
Anti-GAPDH rabbit FL-335; Santa Cruz 
 
Table 2: Secondary antibodies 
Antibody Host Manufacturer 
Anti-rabbit Alexa 488 donkey Abcam 
Anti-rabbit Alexa 594 donkey Abcam 
Anti-mouse Alexa 488 donkey Abcam 
Anti-mouse Alexa 594 goat Abcam 
Anti-rabbit-HRP ? Chemicon (part of Merck, Darmstadt) 
Anti-mouse-HRP ? Chemicon 
 
 
4.2. Agonists and inhibitors 
 
Glutamate sodium salt  Sigma-Aldrich (St. Louis, U.S.A.) 
Glycine    Carl Roth GmBH (Karlsruhe)   
NMDA     Tocris Bioscience (Bristol, U.K.)  
AMPA     Tocris Bioscience 
(+)-MK801 maleate (Dizocilpine) Tocris Bioscience 
Ifenprodil hemitartrate  Tocris Bioscience 
NBQX     Tocris Bioscience 
Sulfasalazine    Sigma-Aldrich 
NU7441    Tocris Bioscience 
ICRF193    Santa Cruz  
KG501     Sigma-Aldrich 
Merbarone    Sigma-Aldrich 
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4.3. Solutions 
 
Ca2+-Imaging  
Imaging buffer 140 mM NaCl; 2.8 mM KCl; 1.8 mM CaCl2; 10 mM HEPES; 20 mM 
Glucose; 10 µM EDTA; pH 7.2  
Immunofluorescence staining 
PBG     PBS+0.05% gelatin 
Blocking buffer   PBG+5% goat serum+0.5% BSA 
Antibody buffer   PBG+5% goat serum 
 
Western Blot 
Lysis buffer 20 mM Tris-HCl (pH 7.5); 150 mM NaCl; 1 mM Na2EDTA; 1 mM 
EGTA; 1% Triton; 2.5 mM sodium pyrophosphate; 1 mM b-
glycerophosphate; 1 mM Na3VO4; 1 μg/ml leupeptin (cell 
signaling #9803) 
4x Loading buffer  240 mM Tris/HCL (pH6.8); 40% glycerol; 8% SDS; 0.04% 
bromphenol blue 
10% SDS gel 33% v/v Rotiphorese (37.5:1); 250 mM Tris-HCl (pH 8.8);  
0.01% w/v SDS; 0.01% w/v Ammonium persulfate;  
0,001% v/v Tetramethylethylenediamine 
SDS-PAGE running-buffer  25 mM Tris; 192 mM glycine, 0.1% SDS  
Anode buffer    60 mM Tris; 40 mM 6-Aminocapric acid; 20% Methanol 
Cathode buffer   60 mM Tris; 40 mM 6-Aminocapric acid; 0.1% SDS 
TBS-T     50 mM Tris; 150 mM NaCl; 0.1% Tween-20 
Blocking buffer   5% milk in TBS-T (0.1% Tween-20) 
Antibody buffer   1% milk in TBS-T (0.1% Tween-20) 
 
Electrophysiological Measurements: 
External solution 4 mM KCl; 140 mM NaCl; 2 mM, CaCl2 5 mM D-Glucose; 
10 mM HEPES/NaOH; pH 7.4; ~298 mOsmol 
Internal solution  50 mM KCl; 10 mM NaCl; 60 mM KF; 20 mM EGTA;  
10 mM HEPES/KOH; pH 7.3; ~285 mOsmol 
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4.4. Cell lines and cell culture 
 
The immortalized human GBM cell lines LN229 and U-87 MG were kindly provided by Prof. Franz 
Rödel (Frankfurt University Hospital, Frankfurt am Main). Both cell lines are IDH1-wt and were 
cultured at 37°C under humid atmosphere and 5% CO2 in T75 flasks (Sarstedt, Nümbrecht) using 
DMEM (Sigma-Aldrich) including ~400 µM glycine and supplemented with 10% FCS (Sigma-Aldrich), 
100 U/ml penicillin/0.1 mg/ml streptomycin (Sigma-Aldrich) and 2 mM L-glutamine (Sigma-Aldrich). 
LN229 and U-87 MG cells were not used for more than 15 passages. 
 
The primary human GBM cell line G1702 was kindly provided by Prof. Donat Kögel (Frankfurt 
University Hospital, Frankfurt am Main). The G1702 cell line was established from a biopsy of a male 
patient and classified as glioblastoma multiforme. The cells are IDH1-wt, ATRX-positive and carry a 
hypermethylation of the MGMT promoter. The G1702 cells were cultured at 37°C under humid 
atmosphere and 5% CO2 in T75 flasks (Sarstedt) as spheres in Neurobasal Medium (Gibco, trade mark 
of Thermo Fisher Scientific, Waltham, U.S.A.) including ~400 µM glycine and supplemented with 2% 
B27 (Gibco), 100 U/ml penicillin/0.1 mg/ml streptomycin (Sigma-Aldrich), 2 mM L-glutamine 
(Sigma-Aldrich), 20 nM EFG (R&D systems, Minneapolis, U.S.A.) and 20 nM FGF2 (Sigma-Aldrich). 
We received the G1702 at passage 30 and used them not longer than 10 passages. 
 
4.5. Immunofluorescence staining (General Protocol) 
 
2*104 LN229 cells or 4*104 U-87 MG cells were seeded in µ-slides VI0,4 (Ibidi, Planegg) in a total 
volume of 150 µl/channel. Next day the cells were fixed with 4% PFA in PBS for 15 min at RT, 
permeabilized with 0.1 % Triton X-100 in PBS and stained with Hoechst 33342 for 10 min at RT. Then 
cells were blocked for at least 1 h RT and incubated with primary antibodies overnight at 4°C. Next 
day samples were washed three times with PBG for 10 min, incubated with anti-rabbit/mouse Alexa 
Fluor 488/594 labeled secondary antibody (1:400) for 1 h at RT and washed three times for 10 min 
with PBG and twice with PBS. 
 
G1702 cells were stained with the same protocol except following differences: G1702 spheres were 
dissociated through repeated pipetting and Accutase (Sigma-Aldrich) treatment for 1-2 min To get 
adherent culture, 5*104 cells were seeded into µ-slides VI0,4 (Ibidi), coated with 2 µg/cm² laminin 
(Sigma-Aldrich) overnight. 
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4.6. Immunofluorescence staining of NMDAR subunits 
 
LN229 and G1702 cells were stained as described (4.5) and no treatment was applied. The following 
combinations of primary and secondary antibodies were used (antibody dilutions in brackets). 
 
anti-GluN1 (1:100)  + donkey anti-rabbit Alexa 488 (1:400) 
anti-GluN2A (1:100)  + donkey anti-mouse Alexa 488 (1:400) 
anti-GluN2B (1:200)  + donkey anti-mouse Alexa 488 (1:400) 
 
The samples were imaged with the inverted epifluorescence microscope Axio Observer Z1 (Zeiss, 
Oberkochen) using a 20x objective. The images were linearly edited with the Fiji software. 
   
4.7. Analysis of 53BP1 and Top2β foci 
 
LN229, U-87 MG and G1702 cells were seeded as described (4.5) and treated directly after seeding as 
indicated. Next day, the samples were treated with 20 µM EdU for 30 min before fixation. Then the 
samples were stained according to the general protocol (4.5). After permeabilization, EdU was 
detected with a Click-iT EdU imaging kit, following the manufacturer instructions (Thermo Fisher 
Scientific) using Alexa Fluor 594 azide or 647 azide (Thermo Fisher Scientific) and 80 µl reaction 
buffer/channel. The following combinations of primary and secondary antibodies were used (antibody 
dilutions in brackets). 
 
anti-53BP1 (1:1000)  + donkey anti-rabbit Alexa 488 (1:400)  
anti-Top2β (1:100)  + goat anti-mouse Alexa 594 (1:400) 
 
For foci counting the immunofluorescent stained samples were imaged with a 20x objective on the 
inverted epifluorescence microscope Axio Observer Z1 (Zeiss). Single nuclei were detected by the 
µManager software based on area size and shape of the Hoechst33342 signal. Then, the integrated 
density of the Hoechst 33342 signal of single nuclei was measured by the µManager software and 
blotted against their mean EdU signal. This blot allowed discrimination between G1 phase cells with 
low Hoechst 33342 and low/no EdU signal, S-phase cells with intermediate Hoechst 33342 and high 
EdU signal and G2-phase cells with high Hoechst 33342 and low/no EdU signal. For foci counting non-
S-phase cells or G1-phase cells were manually gated (see Figure 7), depending on the experimental 
setup. Then, single cells were relocated and foci manually counted using a 63x objective. The foci of at 
least 40 single cells per condition and experiment were counted and the mean of all single cell values 
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of all independent experiments were used for statistical analysis. Mann-Whitney-Test (MWT) was used 
for statistics (GraphPad Prism 7.0, San Diego, U.S.A.). 
 
 
Figure 7: Representative gating of cell cycle phases. The micro-manager software was used to plot the integrated density of 
the Hoechst signal against the mean EdU signal of a cell. Each yellow point represents the calculated values for one cell. The 
gates were manually set for each experiment. 
 
4.8. Cell cycle analysis 
 
LN229 cells were seeded as described (4.5) and treated directly after seeding as indicated. Next day, 
the samples were treated with 20 µM EdU for 30 min. before fixation. Then the samples were stained 
according to the general protocol (4.5). After permeabilization, EdU was detected with a Click-iT EdU 
imaging kit, following the manufacturer instructions (Thermo Fisher Scientific) using Alexa Fluor 594 
azide (Thermo Fisher Scientific) and 80 µl reaction buffer/channel. The cells were imaged with a 20x 
objective on an inverted epifluorescence microscope as described (4.7). At least 1000 cells per 
experiment were gated manually and the cell cycle distribution was calculated. Student´s t-test was 
used for statistics (GraphPad Prism 7.0). 
 
4.9. High-content microscopy 
 
LN229 cells were stained as described above (4.7) but without staining against Top2β. EdU was 
labeled with Alexa azide 594. The samples were imaged via the Operetta High-Content Imaging 
System (PerkinElmer, Waltham, U.S.A.) using a 40x high NA objective. The Harmony analysis software 
was used to select single nuclei based on the shape and intensity of the Hoechst 33342 signal. The EdU 
signal was used to exclude S-phase cells and foci were automatically counted in the 53BP1 channel 
using the “spot analysis” feature. The same thresholds were set for all samples and at least 1500 cells 
per condition were counted. No statistical analysis was done since only one independent experiment 
was performed. 
   27 
4.10. Calcium imaging 
 
2.5*104 LN229 cells were seeded into 8-well µ-slides (Ibidi). Next day, the cells were treated with the 
calcium dye Fluo-4 AM (Thermo Fisher Scientific) dissolved in DMSO for 30 min. to a final 
concentration of 2 µM. The cells were washed once with the imaging buffer and imaged on an 
epifluorescence microscope (Zeiss). Alterations in fluorescence intensity of Fluo-4 were measured with 
a GFP filter by taking an image every second. Glutamate and glycine were applied to the cells to an 
end-concentration of 1 mM and 100 µM respectively after 20 seconds and 10 µM Ionomycin was given 
after 90 seconds. The image sequences were analyzed for visual inspection and processed by using Fiji 
software by subtracting the mean background of the integrated density of every cell and then 
normalized all values to the fist and the highest value of every cell. The data were plotted as relative 
fluorescence intensity scale versus time. Cells which showed an unsteady Fluo-4 signal before 
application were excluded from analysis. Representative images are displayed in false color to 
highlight local differences of Fluo-4 fluorescence intensity. The images were linearly edited with the 
Fiji software. 
 
4.11. Western Blot 
 
For western blot analysis 7*105 LN229 cells were seeded in T25 culture flasks (Sarstedt) or 2*105 
G1702 cells were seeded in 6-well plates (Starlab, Hamburg) and treated overnight as indicated. On 
the next day the cells were washed once with ice cold PBS and lysed in 120 µl (T25) or 40 µl (6-well 
plate) ice cold lysis buffer containing 1 mM pefabloc® (Carl Roth). Protein concentrations were 
determined using a BCA protein assay kit following the manufacturers protocol (Thermo Fisher 
Scientific) and ~30-60 µg protein were mixed with 4x SDS-loading buffer containing 100mM DTT, 
denaturized at 64°C for 10 min. and loaded on 6%-12% gradient gel or 10% continuous gel per lane. A 
protein ladder with a size of 10-180 kDa (Thermo Fisher Scientific) was used as marker. The proteins 
were separated in running buffer on ice at constant 120-130 V. A discontinuous approach with 
separate buffers for anode and cathode was used to transfer the separated proteins to a PVDF 
membrane (Merck Millipore, Burlington, U.S.A.). The blotting was performed in a semi-dry transfer 
system (Biorad, Hercules, U.S.A) for 36 min. at constant 15 V. Afterwards, the blots were blocked for 
1 h at RT, treated with anti-cFos antibody (1:2000) or anti-Top2β (1:500) and anti-GAPDH (1:2000) 
diluted in antibody buffer overnight at 4°C. Then the blots were washed 3 times for 10 min. with TBS-
T and incubated with anti-mouse/anti rabbit HRP conjugated secondary antibody (1:10000) for 1 h at 
RT and washed again 3 times for 10 min. Immunoblots were detected using luminol reagent (Thermo 
Fisher Scientific or Merck Millipore) in the ChemiDoc MP imaging system (BioRad). Quantitative 
analysis was done with the Image Lab software (BioRad). All band intensities were normalized to the 
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intensity of the GAPDH band in the same lane and the cFos/GAPDH ratios were normalized to the 
control treatment of the experiment. For statistics one sample t tests were used (GraphPad Prism 7.0). 
 
Irradiation with X-ray for Western Blot 
Western Blot samples were irradiated directly after seeding and treatment with agonists/inhibitors. 
The samples were irradiated in an X-ray tube with tungsten anode (Philips, Amsterdam, Netherlands) 
at 33.7 mA and 90 kV with a dose rate of 1.162 Gy/min (Fricke dosimetry) and at 45 cm distance 
using 1 mm aluminum filter. 
 
4.12. Transfection with siRNA 
 
For siRNA transfection, 6*105 LN229 cells were seeded in T25 flasks (Sarstedt) overnight and 
transfected with 16µg si-RNA next day (si1 UCGGGCUAGGAAAGAAGUAA(UU); si2 
CAGCCGAAAGACCUAAAUACA(UU) (Eurofins Scientific, Luxemburg); sequence described by Kamaci 
et al. 2011 [132]) according to the manufacturers protocol with the K2 transfection System (Biontex, 
München). As a control, the cells were treated only with K2 transfection reagent, but without siRNA. 
The transfected cells were used for experiments after 24 h. 
 
4.13. Clonogenic survival 
 
LN229 cells transfected with or without Top2β siRNA were trypsinized and seeded into 6 well plates 
(Sarstedt) as triplets and treated with 1 mM Glu or 1 mM Glu/20 µM ifenprodil. Untransfected cells 
were used as an additional control. The number of seeded cells depended on the treatment and X-ray 
dose as shown in the following table: 
 
Table 3: Number of seeded cells for clonogenic survival assay 
Treatment 0 Gy 2 Gy 4 Gy 6 Gy 
Glu 
Glu/Sham transfected 
500 cells/well 500 cells/well 1000 cells/well 2000 cells/well 
Glu/ifenprodil 
Glu/siRNA transfected  
750 cells/well 750 cells/well 1500 cells/well 3000 cells/well 
 
The cells were allowed to attach for 3 h and then irradiated in an X-ray tube with tungsten anode 
(Philips) at 33.7 mA and 90 kV with a dose rate of 1.162 Gy/min (Fricke dosimetry) and at 45 cm 
distance using 1 mm aluminum filter. Non irradiated cells were placed in the radiation chamber for 
100 s without irradiation. Colonies were allowed to form for 8 days, fixated with 70% ethanol and 
stained with 0.1% crystal violet in 25% ethanol. The colonies with more than 50 cells were manually 
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counted under a binocular using 65x-150x magnification. The plating efficiencies (PE) were 
determined depending on the number of seeded cells: 
 
𝑃𝐸 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
 
The survival fraction (SF) was calculated by dividing the PE of each dose by the PE of the non-
irradiated cells. The values of three independent experiments were fitted to a linear quadratic 
mathematical model by GraphPad Prism software with the equation: 
 
𝑆𝐹 = 𝑒(−𝛼𝐷−𝛽𝐷
2 ) 
 
Where (SF) is the surviving fraction and (D) is the x-ray dose. Additionally, the relative survival ratio 
was calculated out of the mean value of all three experiments. The relative survival ratio is SF of 
untreated cell divided by SF of treated cells. For statistical analysis student´s t-test was used 
(GraphPad Prism 7). 
 
4.14. BDNF Assay 
 
For the measurement of extracellular BDNF concentrations 2*104 LN229 cells/well were seeded into 
24-well plates (Sarstedt) and treated directly after as indicated. Next day the supernatants were 
collected and centrifuged at 16200 g for 5 min. to remove remaining cells and debris. The BDNF 
concentration of the supernatants was measured with a human BDNF ELISA Kit (Abcam, ab99978) 
following the manufacturers protocol. In short, BDNF is bound to immobilized anti-human-BDNF 
antibody and then coupled to HRP via biotinylated anti-BDNF-antibodies. TMB substrate solution is 
added and color develops in proportion to the amount of BDNF bound. Then absorbance at 450 nm 
was measured with a TECAN Infinite M 200 microplate reader (Männedorf, Schweiz). All treatments 
were done as triplets and the concentration of BDNF was normalized to the mean value of the SAS/Glu 
treated sample. One sample t-test was done for statistics (GraphPad Prism 7). 
 
Irradiation with X-ray for BDNF-Assay 
Samples were irradiated 30 min. after seeding and treatment with agonists/inhibitors inside 24-well 
plates. The samples were irradiated in an X-ray tube with tungsten anode (Phillips) at 33.7 mA and 
90 kV with a dose rate of 1.162 Gy/min (Fricke dosimetry) and at 45 cm distance using 1 mm 
aluminum filter. 
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4.15. Electrophysiological measurements of G1702 cells 
 
Electrophysiological measurements of G1702 cells have been performed by M.Sc. Juliane Joswig. For 
this, ~4*105 G1702 cells were seeded into a 35 mm cell culture dish (Sarstedt), coated with 2 µg/cm² 
laminin (Sigma-Aldrich). Once in following three days, the media was removed and cells were covered 
external solution for patch clamp recordings. Coated (Sigmacote®, Sigma-Aldrich) borosilicate 
capillaries (length 10 cm, outer diameter 1.5 mm, inner diameter 1.17 mm) were pulled in two steps 
with a micropipette Puller PC-10 (Narishige, Tokyo, Japan) to patch-pipettes with a resistance of 6 Ω 
to 10 Ω, which were filled with internal solution. Cells were measured in whole-cell configuration. For 
this, the membrane potential was clamped to -70 mV for ~10 s. After ~3 s perfusion systems were 
manually switched and cells were now perfused with external solution containing 1 mM Glu/100 µM 
Gly for ~ 3s. After this, perfusion was again switched to external solution for additional ~3 s. Cells 
which showed a current upon Glu/Gly perfusion which was at least twice as high as the current 
background noise and which could be washed out with external solution without Glu/Gly were 
counted as responsive. The maximal (Imax) current after Glu/Gly application was analyzed with IGOR 
(WaveMetrics, Portland, U.S.A.).  
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5. Results 
 
All figures presented in the chapters “results” and “discussion” have been created by Henrik Lutz. The 
figures 9, 10(a,b and d), 11, 12, 13, 14, 15a, 16(b-d), 17 (a+b) and 19 have been published in similar 
or identical form as “NMDA Receptor Signaling Mediates cFos Expression via Top2beta-Induced DSBs in 
Glioblastoma Cells” in cancers [133]. Figures 8 and 15 b have been published in similar or identical 
form as “NMDA Receptor-Mediated Signaling Pathways Enhance Radiation Resistance, Survival and 
Migration in Glioblastoma Cells-A Potential Target for Adjuvant Radiotherapy” in cancers [73]. 
 
 
5.1. Glu induces Ca2+ transients in NMDAR-expressing LN229 cells  
 
The activation of NMDARs by Glu opens the receptors ion channel, allowing cations to flow into (Na+, 
Ca2+) or out (K+) of the cell.  The influx of Ca2+ is a crucial step for NMDAR signaling in neurons and 
cancer cells alike. For this reason the initial step of NMDAR signaling, the entrance of Ca2+, was 
investigated in GBM cells. We chose to analyze the NMDAR-expressing GBM cell line LN229 which 
showed Glu-mediated currents in electrophysiological measurements [73]. 
To validate if Glu also mediates Ca2+ currents, we imaged LN229 cells with the non-ratiometric Ca2+ 
indicator Flou-4 AM. The cells were loaded with Flou-4 and sampled with 1 Hz on an epifluorescence 
microscope. After 20 s 1 mM Glu and 100 µM Gly were applied to the cells and 10 µM Ionomycin after 
90 s (Figure 8a). The diagram shows the relative intensity of two responding (red) and two non-
responding (black) cells over time. The non-responding cells showed a slow, continuous increase of 
relative intensity, which is likely induced by the imaging process itself, but the intensity of responding 
cells showed a faster increase after Glu/Gly application (50% of cells responding, n=10). The 
responding cells displayed a persistent increase of Flou-4 intensity which either stabilized at a certain 
level or oscillated. Slow oscillation with a high amplitude were caused by changes of the relative 
intensity inside the nuclear area (Figure 8bi), while fast oscillations with low amplitude were caused 
by local changes of the relative intensity inside cell protrusions (blue arrow; Figure 8a and bii). These 
results demonstrate that application of Glu/Gly is able to induce transient Ca2+ currents as well as a 
longer lasting increase of nuclear Ca2+ in LN229 cells.  
We next analyzed the expression pattern of NMDAR subunits in LN229 cells via immunofluorescence 
staining. GluN1, GluN2A and GluN2B subunits were expressed in LN229 cells (Figure 8c). 
Remarkably, high amounts of the subunits could be seen in the ER but also in the cells protrusions and 
lamellipodia (blue arrows). The localization of NMDAR subunits is similar to the localization of fast 
Ca2+ oscillations seen after Glu/Gly application.  
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Figure 8: Glu-mediated Ca2+ transients and NMDAR expression in LN229 cells. (a) Ca2+-imaging of LN229 cells loaded with 
Fluo-4 shows an increase of intracellular Ca2+ in half of the cells after application of Glu/Gly (n=10). The diagram displays the 
relative Fluo-4 fluorescence over time of two cells responding (red) and two cells non-responding (black) to the application of 
1 mM Glu/100 µM Gly (t=20 s). 10 µM ionomycin were given after 90s as an internal control. Blue arrow indicates a short 
oscillation with low amplitude. (b) i) Representative images of Flou-4 loaded cells before (t=0 s) and after (t=74 s) application 
of 1 mM Glu/100 µM Gly at t=20 s. The increased fluorescence intensity demonstrates an increased concentration of Ca2+ in 
the nuclear area, with different strong response of individual cells (scalebar: 10 µm). ii) Representative images of Flou-4 loaded 
cells after application of 1 mM Glu/100 µM Gly at t=20 s. Local oscillations of the Ca2+-signal can be observed at cell 
protrusions (blue arrow; scalebar: 10 µm). (c) Immunofluorescence staining of the NMDAR subunits GluN1, GluN2A and 
GluN2B. All subunits are expressed in LN229 cells, especially at cell protrusions (blue arrows) and also in the ER (Hoechst 
33342=blue, NMDAR subunits=green, scalebar: 25 µm). 
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5.2. Glu induces DSBs upon NMDAR activation in GBM cell lines 
 
As demonstrated in 5.1, LN229 cells show Glu-mediated Ca2+ influx, which represents the initial step 
of NMDAR signaling. Moving forward, we analyzed if a characteristic step of NMDAR signaling to 
promote gene expression can be found in LN229 cells: The induction of Glu-dependent DSBs upon 
NMDAR activation [104]. 
 
 
5.2.1. Glutamate-induced DSBs in LN229 cells 
 
In order to check if LN229 cells use Glu-induced DSBs, the number of DSBs was quantified by 
immunostaining of 53BP1 foci after Glu treatment. In a first experiment, LN229 cells were treated with 
250 µM sulfasalazine (SAS) which inhibits the endogenous release of Glu by the system xc
- antiporter 
and the number of 53BP1 foci in non-S-phase cells (EdU negative cells) were counted. SAS treated 
LN229 cells showed a mean number of 1.9±0.2 53BP1 foci/cell (Figure 9a), but cells which were 
additionally treated with 1 mM Glu showed a significantly increased number of 53BP1 foci (3±0.3; 
p<0.0001; Figure 9a) indicating that Glu also induces DSBs in LN229 cells. 
 
 
Figure 9: Glu induces transient DSBs in LN229 cells. Experiments included in this figure were performed by Thy Anh Nguyen. 
(a) Overnight treatment with 1 mM Glu increases the mean number of 53BP1 foci/cell in non-S-phase LN229 cells cultivated 
with 250 µM SAS. Depletion of Glu leads to a reduction of foci to the basal level after 0.5h (n=3; 40 cells/n, error bars show 
SEM, bar graphs show the mean of all single values). (b) The reduction of 53BP1 foci was delayed for 2 h when 1 µM NU7441 
was given at the time point of Glu depletion (LN229 cells treated with 250 µM SAS and 1 mM Glu overnight). Overnight 
treatment with 1 mM Glu and 1 µM NU7441 increased the number of 53BP1 foci compared to Glu treated LN229 cells. (n=3; 
40 cells/n; error bars show SEM; bar graphs show the mean of all single values). (Mann-Whitney Test for statistics; p>0.05 (ns), 
p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)) 
 
   34 
Next, we wanted to see how persistent Glu-mediated DSBs in GBM cells are. For this LN229 cells were 
treated with 1 mM Glu/250 µM SAS overnight and Glu was depleted next day. Again, 53BP1 foci were 
counted in non-S-phase cells. Glu depletion decreased the number of 53BP1 foci to 1.9±0.1 
(p=0.0019) after 0.5 h, which is similar to the number of SAS treated LN229 cells without Glu 
treatment (Figure 9a) and the number of foci/cell did not increase until 2 h after depletion (1.5±0.1). 
These results indicate that Glu-mediated DSBs are not persistent in LN229 cells. To check whether 
53BP1 foci decrease after Glu depletion is facilitated by classical DNA repair pathways, the same 
experiment was done again, but additionally the catalytic subunit of the DNA-dependent protein 
kinase (DNA-PKcs) was inhibited with 1 µM NU7441 at the time point of Glu depletion (Figure 9b). 
DNA-PKcs is required for NHEJ, a repair pathway which occurs in G1-, S- and G2-phase cells. In this 
experiment the number of 53BP1 foci/cell was again significantly increased when LN229 cells were 
treated with Glu and SAS (3.9±0.3) compared to cells treated with SAS alone (1.4±0.1; p<0.0001). 
Strikingly, the number of 53BP1 foci was no longer decreased 0.5 h after Glu depletion (3.0±0.2) 
when NU7441 was added simultaneously. After 2 h a significant decrease to 1.8±0.2 foci/cell 
(p<0.001) was found, indicating that Glu-mediated DSBs are more persistent upon DNA-PKcs 
inhibition (Figure 9b). Additionally, overnight treatment with Glu and NU7441 leads to a significant 
increase of 53BP1 foci (4.9±0.3; p<0.001) compared to cells solely treated with Glu. 
 
 
5.2.2. Glu induces DSBs in a subpopulation of LN229 cells 
 
Our results could show that the mean number of DSBs, indicated by 53BP1 foci, increases upon Glu 
treatment in LN229 cells. Interestingly, the number of DSBs within individual LN229 cells highly 
differed (Figure 10a), which led us to the hypothesis that only a fraction of LN229 cells respond to 
Glu treatment with induction of DSBs. To increase the visibility of subpopulations within the LN229 
cells, the induction of 53BP1 foci was analyzed in a high number of cells using automated, high-
content microscopy. Therefore, the cells were treated with 250 µM SAS with or without 1 mM Glu or 
left untreated and 53BP1 foci were automatically counted in at least 1500 non-S-phase cells. Similar to 
our first results, the number of foci/cell in SAS treated cells was increased from 0.3±0.02 to 1.9±0.1 
after Glu treatment (Figure 10b). The untreated cells reached a value of 1.7±0.1 foci/cell, which is 
similar to Glu treated cells, confirming the effectiveness of SAS in reducing the number of 53BP1 foci.  
Since a specific number of genomic loci had been identified to be the target of stimulus-induced DSBs 
upon NMDAR activation in neurons, we ask if Glu also induces a specific number of DSBs in a 
subpopulation of LN229 cells. The histogram of 53BP1 foci/cell for SAS (red) and SAS/Glu (black) 
treated cells (Figure 10c) shows a shift from zero or low numbers of foci/cell to higher numbers of 
foci/cell upon Glu treatment. A low peak at 10 foci/cell could be supposed but this assumption could 
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not be verified since only one experiment was performed. Notably, all numbers of foci between 0-20 
could be found in Glu treated LN229 cells, but only four cell had more than 20 foci. 
 
 
Figure 10: Glu induces DSBs in a subpopulation of LN229 cells. (a) Representative immunofluorescence staining of LN229 
cells treated with 250 µM SAS or 250 µM SAS/1 mM Glu (53BP1 = Green, EdU = red, Hoechst = blue). Note that LN229 cells 
show a heterogeneous distribution of 53BP1 foci after Glu treatment (Scalebar: 25µm). (b-d) High throughput counting of 
53BP1 foci in LN229 cells treated with 250 µM SAS or 250 µM SAS/1 mM Glu or untreated (n=1; >1500cells/n). (b) Cells treated 
with Glu and untreated cells show a higher number of 53BP1 foci/cell (mean±SEM). (c) Histogram of 53BP1 foci/cell for SAS 
(black) and SAS/Glu (red) treated cells. Glu does not induce a specific number of foci. (d) Distribution of 53BP1 foci/cell within 
the cell population. About 80% of the cells have no foci when treated with SAS but the number of cells without foci decreases 
in the presence of Glu. Glu treatment increases the low (1-3) and high (>3) numbers of foci in LN229 cells indicating 
differential response of subpopulations.  
 
However, to characterize how cells respond to Glu with the induction of foci, they were sorted into 3 
groups, bearing no, a low number (1-3) or a high number (>3) of 53BP1 foci (Figure 10d). 81.4% of 
all cells treated with SAS had no foci and 17.4% showed between 1 and 3 foci. After Glu treatment 
45.4% of all cells showed no foci, indicating that 36% of the cells specifically reacted to Glu by DSB 
induction. Furthermore, the results demonstrate that nearly half of the cells did not respond to Glu 
treatment at all. The proportion of cells with 1-3 foci/cell increased to 37.6% for Glu treated cells as 
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well as the number of cells with higher amounts of DSBs from 1.1% to 17.0%. These results confirm 
the existence of Glu-mediated DSBs with an automated approach and demonstrate that Glu-mediated 
DSBs do not occur in all LN229 cells. 
 
 
5.2.3. DSB induction depends on NMDAR activation 
 
The Glu-mediated induction of DSBs in LN229 cells could be demonstrated, but it is unclear which 
GluRs contribute to the induction of DSBs. In neurons, induction of DSBs is mediated by NMDARs, 
suggesting that NMDARs are also needed for the induction in GBM cells [104]. On the other hand, 
GBM cells show an especially high expression of Ca2+-permeable AMPARs, indicating a dominant role 
of AMPARs in GBM cells [40]. 
To find the contribution of NMDARs and AMPARs we analyzed the number of 53BP1 foci after 
application of the specific agonists AMPA and NMDA. The endogenous release of glutamate was again 
inhibited with 250 µM SAS, and LN229 cells were treated with 1 mM Glu, 100 µM NMDA or 100 µM 
AMPA overnight and 53BP1 foci in non-S-phase cells were quantified (Figure 11a). First of all, Glu 
treatment significantly increased the number of 53BP1 foci/cell to 2.3±0.2 compared to cells only 
treated with SAS (1.3±0.1; p<0.0001) which closely matches the number of foci/cell of untreated 
cells (2.4±0.2). NMDA treatment led to a number of 53BP1 foci (2.3±0.2; p<0.0001) which is 
comparable to Glu treated cells, whereas addition of AMPA showed a significantly lower number of 
foci compared to NMDA treatment (1.8±0.2; p=0.016). To verify the contribution of NMDARs and 
AMPARs to Glu-mediated induction of DSBs, LN229 cells were treated with Glu in the presence of the 
specific AMPAR antagonist NBQX (100 µM) or the NMDAR antagonist ifenprodil (20 µM). Addition of 
ifenprodil resulted in a significant decrease of 53BP1 foci (1.6±0.2; p<0.001, Figure 11a) compared 
to sole Glu treatment, whereas addition of NBQX led to a significant lower decrease of 53BP1 foci 
compared to ifenprodil (1.95±0.16; p=0.026). The higher induction of 53BP1 foci upon NMDA 
compared to AMPA treatment and the significantly higher decrease of foci upon ifenprodil compared to 
NBQX treatment, lead to the assumption that Glu-mediated DSBs are dominantly induced upon 
NMDAR activation. Although AMPARs show a minor ability to induce DSBs their contribution to Glu-
mediated DSBs was neglected in the succeeding experiments. 
In order to proof, that the induction of NMDAR-dependent DSBs is not restricted to LN229 cells, we 
checked if another NMDAR-expressing cell line also shows induction of DSBs upon NMDAR activation. 
We therefore analyzed the induction of 53BP1 foci upon Glu treatment in U-87 MG cells, since they 
showed functional expression of NMDARs in electrophysiological experiments [73]. Again, the 
endogenous release of glutamate was inhibited with 250 µM SAS, and U-87 MG cells were treated with 
1 mM Glu overnight. Glu treatment increased the number of 53BP1 foci/cell significantly to 2.2±0.2 
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(p<0.001) compared to cells solely treated with SAS (1.3±0.1), demonstrating the existence of Glu-
induced DSBs also in U-87 MG cells (Figure 11b). To check if the foci induction is dependent on 
NMDAR activation we treated the cells with NMDA (100 µM), which significantly increased the 
number of foci/cell to 2.7±0.2 (p<0.001). For validation of the NMDAR-dependent effect, the cells 
were treated with 1 mM Glu and the NMDAR blocker MK801 (20 µM) and the GluN2B specific 
inhibitor ifenprodil (20 µM). MK801 significantly decreased the number of foci/cell to 1.8±0.2 
(p=0.014), while specific inhibition of NMDAR containing the GluN2B with ifenprodil did not lead to 
a significant decrease (1.9±0.2; p=0.13). However, these results demonstrate that the induction of 
NMDAR-dependent DSBs can be observed in the U-87 MG cell line and is not restricted to LN229 cells.  
 
 
Figure 11: Glu-induced DSBs are mediated by NMDARs. (a) LN229 cells were treated with 250 µM SAS and 1 mM Glu, 100 µM 
NMDA, 100 µM AMPA, 1 mM Glu/20 µM ifenprodil, 1 mM Glu/100 µM NBQX or kept untreated overnight and 53BP1 foci/cell 
of non-S-phase cells were counted. The number of 53BP1 foci/cell increased with Glu as well as with NMDA and reach the 
same level as untreated cells. AMPA induced a significant lower amount of foci than NMDA. Ifenprodil led to a stronger 
decrease of foci than NBQX. (b) U-87 MG cells were treated with 250 µM SAS and 1 mM Glu, 100 µM NMDA, 1 mM Glu/20 µM 
MK801 or 1 mM Glu/20 µM ifenprodil overnight and 53BP1 foci/cell of non-S-phase cells were counted. Treatment with Glu 
and NMDA significantly increases the number of 53BP1 foci/cell compared to SAS treated cells while MK801 reduces the 
number of foci/cell compared to Glu treated cells. Ifenprodil shows no significant decrease of foci. (n indicated in bar 
diagrams; 50 cell/n; bar graphs show the mean of all single values; error bars show SEM; Mann-Whitney Test; p>0.05 (ns), 
p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)) 
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5.3. NMDAR-dependent DSBs are associated with Top2 activity in LN229 cells 
 
GBM cells show NMDAR-dependent induction of DSBs. Such DSBs are inflicted by Top2β in neurons in 
order to promote NMDAR-dependent gene transcription [104]. To check if GBM cells and neurons use 
the same NMDAR signaling pathway to promote transcription, we analyzed the impact of Top2β on 
NMDAR-mediated DSB induction and considered the impact of cell cycle progression on DSB 
induction. 
 
 
5.3.1. Cell cycle effects on Glu-mediated DSBs 
 
By now, it is unclear how NMDAR activation induces DSBs in GBM cells. One possibility is that 
NMDAR activation could impact the cells progression through cell cycle and therefore alters the 
proportion of G1 and G2 phase cells. Since some DSBs, which occur during replication in S-phase, 
remain unrepaired as cells process through cell cycle, the number of DSBs in G2 phase often is higher 
than in G1-phase. To rule out the possibility that NMDAR-dependent DSBs are a result of alterations in 
G1/G2-phase ratio we decided to count 53BP1 foci in a single cell cycle phase. We chose to count 
53BP1 foci in G1-phase cells because most transcriptional activity happens in the G1-phase of the cell 
cycle [134, 135]. Based on the fact that Glu-mediated DSBs have a regulative function in the 
transcription of several genes in neurons, we expected that Glu-mediated DSBs should be especially 
present in G1-phase LN229 cells. 
Therefore, we treated LN229 cell with 250µM SAS and 1 mM Glu, 100 µM NMDA or 1 mM Glu and 
20 µM ifenprodil and counted the number of 53BP1 foci in G1 phase cells only (Figure 11Figure 12a). 
Glu treatment significantly increases the number of foci/cell to 2.8±0.2 (p<0.001) compared to cells 
only treated with SAS (1.8±0.1) which matches the number of foci/cell in untreated cells (2.8±0.3). 
Treatment with NMDA significantly increased the number of 53BP1 foci to 2.3±0.2 (p=0.013). These 
results show that Glu-mediated DSBs occur in G1-phase LN229 cells. However, inhibition of NMDARs 
with ifenprodil led to no significant decrease of foci/cell (2.1±0.1; p=0.08) compared to Glu 
treatment.  
To rule out other cell cycle-dependent effects on the number of DSBs, we additionally performed a cell 
cycle analysis in LN229 cells via EdU. When the cells were treated with 250 µM SAS and 1 mM Glu or 
100 µM NMDA overnight no changes of the cell cycle could be detected (Figure 12b). The percentages 
of cells in G1 phase were 28.5±2.8%, 28.6±0.6% and 29.6±1.3% after SAS, SAS/Glu and SAS/NMDA 
treatment, respectively. In the same order the values were 61.2±6.2%, 62.1±4.5% and 60.1±5.9% for 
S-phase and 10.3±3.8%, 9.3±4.8% and 10.3±4.2% for G2-phase. These results show that the 
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induction of 53BP1 foci upon Glu treatment does not rely on changes in the cell cycle, but likely is the 
result of an active DSB induction upon NMDAR activation. 
 
 
Figure 12: Cell cycle effects on Glu-mediated DSBs. (a) Analysis of 53BP1 foci/cell in G1 phase LN229 cells treated with 
250 µM SAS and 100 µM NMDA, 1 mM Glu, 1 mM Glu/20 µM ifenprodil or untreated overnight. Significant increase of 53BP1 
foci/cell with NMDA or Glu but no significant reduction with 20 µM ifenprodil compared to Glu treatment. (n indicated in bar 
diagrams, 50 cell/n, bar graphs show the mean of all single values; error bars show SEM; Mann-Whitney Test). (b) Cell cycle 
analysis of LN229 cells treated with 250 µM SAS and 1 mM Glu or 100 µM NMDA overnight. Treatment with iGluR agonists did 
not change the cell cycle distribution. Phases were gated by EdU and Hoechst signal. (n indicated in bar diagrams; at least 
1000 cells/n; error bars show SEM; students t-test). (p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)) 
 
 
5.3.2. Top2 inhibition prevents NMDAR-dependent DSB induction 
 
The role of Top2 activity for the induction of NMDAR-dependent DSBs was investigated in LN229 cells. 
Therefore, the cells were treated with 1 mM Glu or with 1 mM Glu and 100 nM ICRF193, an catalytic 
inhibitor of Top2 [136]. Additionally, samples were treated with 1 mM Glu and 20 µM MK801, a 
specific NMDAR blocker or 1 mM Glu and 20 µM MK801 and 100 nM ICRF193. All samples were 
treated overnight and 53BP1 foci were counted in G1-phase cells. Glu treated cells had a mean number 
of 2.4±0.2 foci/cell, which significantly decreased to 1.7±0.2 (p=0.003) when MK801 was added 
(Figure 13). Interestingly, the mean number of foci/cell was 1.8±0.1 after ICRF193 treatment, which 
is only slightly higher than the number of foci after MK801 treatment (ICRF193: 1.754±0.1358 
compared to MK801: 1.733±0.178), but the decrease of foci caused by ICRF193 is statistically not 
significant (p=0.12). Double treatment with ICRF193 and MK801 led to a significant decrease of 
53BP1 foci/cell compared to Glu treated cells (1.5±0.1; p=0.001), but compared to MK801 or 
ICRF193 treated cells double treatment showed no significant decrease. Although ICRF193 did not 
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statistically reduce the number of 53BP1 foci/cell, the amount of 53BP1 foci/cell between MK801 and 
ICRF193 treated cells are remarkably similar. 
 
 
Figure 13: NMDAR-induced DSBs are mediated by Top2. LN229 cells were treated with 1 mM Glu and 20 µM MK801 or 
100 nM ICRF193 or 20 µM MK801/100 nM ICRF193 overnight and 53BP1 foci were counted in G1-phase cells. MK801 
treatment significantly decreased the number of foci, while ICRF193 showed a similar decrease which is not statistically 
significant. Combined MK801/ICRF193 treatment did not significantly decrease the amount of 53BP1 foci, indicating a sub-
additive effect (n=3; 60 cell/n; bar graphs show the mean of all single values; error bars show SEM; Mann-Whitney Test; 
p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)).  
 
 
5.3.3. Top2β is associated with Glu-mediated DSBs 
 
In neuronal Glu signaling Top2β is recruited to the promoter region of several genes, where it induces 
DSBs upon NMDAR activation. We checked if Top2β recruitment to gene sites can be observed in 
immunofluorescence staining. Interestingly, the immunofluorescence staining showed that Top2β 
forms foci structures inside the nucleus of LN229 cells (Figure 14a). Additionally, Top2β foci 
colocalize with 53BP1 foci, indicating induction of DSBs at sites of high Top2β activity.  
To validate the correlation of 53BP1 and Top2β, LN229 cells were treated with 250 µM SAS or 250 µM 
SAS and 1 mM Glu and the amount of 53BP1 foci and Top2β foci per cell were counted in non-S-phase 
cells (Figure 14b). Glu treatment significantly increased the amount of 53BP1 foci from 1.8±0.2 to 
2.4±0.2 (p=0.03) and the number of Top2β foci from 0.9±0.1 to 1.4±0.1 (p=0.01) foci/cell, which 
demonstrates that Glu induces a similar number of 53BP1 and Top2β foci (0.6 and 0.5 foci/cell 
respectively) in LN229 cells. 
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Figure 14: Top2β is accumulated at DSB sites. (a) Representative immunofluorescence staining of LN229 cells treated with 1 
mM Glu overnight. The images of the Hoechst staining as well as the 53BP1 and Top2β immunofluorescence staining are 
displayed as well as a merge image of Top2β (green) and 53BP1 (red). Top2β forms foci structures, which colocalize with 
53BP1 foci (scalebar: 15 µM). (b) LN229 cells were treated with 250 µM SAS or 250 µM SAS and 1 mM Glu and 53BP1 foci and 
Top2β foci were counted in non-S-phase cells. The number of 53BP1 and Top2β foci significantly increased after Glu treatment. 
(n=2; 40 cells/n; bar graphs show the mean of all single values; error bars show SEM; Mann-Whitney Test; p>0.05 (ns), p≤0.05 
(*), p≤0.01 (**), p≤0.001 (***).  
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5.4. Top2β-mediated NMDAR signaling regulates cFos expression in GBM cells and 
promotes radioresistance 
 
So far, the results point out that Glu induces NMDAR-dependent DSBs in LN229 and U-87 MG cells, 
supporting the hypothesis of comparable NMDAR signaling in GBM cells and neurons. As a next step 
we asked if NMDAR-induced DSBs are capable to regulate gene expression in GBM cells as well. We 
therefore chose to analyze expression of the ERG cFos, which is expressed dependent on NMDAR-
induced DSBs in neurons [104] and has also been correlated with GBM radioresistance [98].  
 
 
5.4.1. cFos and BDNF expression are regulated by NMDAR signaling in LN229 cells 
 
First, NMDAR and AMPAR were inhibited with 20 µM MK801/100 µM NBQX overnight and cFos 
expression was quantified in LN229 cells by western blot (Figure 15a). The results showed a high 
variance, reaching from no effect to almost 50% decrease with a mean reduction of cFos expression to 
80±20%. Interestingly, the GluN2B specific antagonist ifenprodil (20 µM), significantly reduced the 
expression of cFos to 75±11% (p=0.02), which indicates the involvement of GluN2B containing 
NMDARs in cFos regulation in LN229 cells. To validate the impact of NMDAR signaling on cFos 
expression we next inhibited two key proteins downstream in the NMDARs signaling cascade. First 
CREB was inhibited with 25 µM KG501, which significantly decreased the relative expression of cFos to 
61±12% (p=0.01) (Figure 15a). Second, Top2 was inhibited with 1 µM ICRF193, which led to a 
down regulation of cFos to 80±4% (p=0.001). Hence, in LN229 cells three different proteins of the 
NMDAR signaling pathway are involved in cFos regulation. 
cFos itself is a transcription factor, which regulates the expression of several genes. In neurons, for 
example, cFos regulates the expression of BDNF, a signaling protein which is important for neuronal 
survival but which also promotes glioma growth and is correlated with tumor grade [15, 137]. 
Therefore, the secretion of BDNF into the culturing media was used to find out whether NMDAR 
signaling is able to regulate the expression of genes downstream of cFos. If Glu release of LN229 cells 
was inhibited with 250 µM SAS overnight, the amount of BDNF secreted into the media significantly 
decreased to 52±13% (p=0.01) compared to cells additionally treated with 1 mM Glu (Figure 15b). 
The relative BDNF concentration of untreated cells was similar to cells treated with Glu and SAS 
(104±9%). These results indicate that BDNF expression is regulated by Glu. 
Next, the impact of NMDAR signaling proteins on BDNF expression was checked. LN229 cells were 
treated with 250 µM SAS/1 mM Glu and NMDARs, CREB or Top2 were inhibited with 20 µM MK801, 
25 µM KG501 or 10 µM merbarone, respectively (Figure 15b). Compared to Glu treatment alone, 
NMDAR inhibition with MK801 led to a non-significant decrease to 68±14% (p=0.69) of BDNF in the 
media, while inhibition of CREB significantly decreased the relative concentration of BDNF to 58±13% 
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(p=0.02). Inhibition of Top2 endonuclease activity with merbarone led to a mean value of 41±18%. It 
must be mentioned, that statistical tests have been performed on the triplet values of two independent 
experiments and for merbarone only a single triplet experiment was performed. Therefore, the validity 
of the results is improvable. However, the tendency for NMDAR, CREB and Top2β inhibition all 
indicate that the expression of BDNF is regulated by NMDAR signaling in LN229 cells. 
 
 
Figure 15: NMDAR signaling regulates expression of cFos and BDNF in LN229 cells. (a) Analysis of cFos expression after 
specific inhibition of NMDAR signaling proteins by western blot. LN229 cells were treated overnight with 1 mM Glu, 1 mM 
Glu/20 µM MK801/100 µM NBQX, 1 mM Glu/20 µM ifenprodil, 1 mM Glu/25 µM KG501 or 1 mM Glu/1 µM ICRF193. 
Representative bands from one experiment are displayed for each treatment and the bar diagram shows the mean intensity 
of cFos/GAPDH normalized to Glu treatment of all experiments. Inhibition of NMDARs with ifenprodil, inhibition of CREB with 
KG501 and inhibition of Top2 with ICRF193 all lead to a significant downregulation of cFos. Bar diagrams show the mean±SD 
of four experiments (one sample t-test; p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)). (b) Analysis of BDNF secretion 
into the cell culture medium after specific activation and inhibition of NMDAR signaling proteins. LN229 cells were treated 
overnight with only media or 250 µM SAS, SAS/1 mM Glu, SAS/Glu/20 µM MK801, SAS/Glu/25 µM KG501 or SAS/Glu/10 µM 
merbarone and BDNF concentrations were measured as triplets with a colorimetric BDNF assay kit and all values were 
normalized to the mean value of SAS/Glu treated samples of each experiment. Inhibition of Glu release with SAS as well as 
inhibition of NMDARs with MK801, inhibition of CREB with KG501 and inhibition of Top2 with merbarone lead to lower 
amounts of BDNF compared to Glu treated samples. Bar diagrams show the mean±SEM of all measured values (n indicated in 
bar diagrams; one sample t-test; p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)). 
 
 
 
 
 
 
 
   44 
5.4.2. NMDAR signaling regulates cFos expression in primary GBM cells 
 
Immortalized cell lines show relatively stable expression patterns and are useful to investigate specific 
signaling pathways under controlled conditions. But cancer cell lines do not reflect the properties of 
primary cancer cells, limiting the transferability of results from cell lines to primary cells. We therefore 
checked if NMDAR signaling also occurs in the primary GBM cell line G1702. 
At first, expression of functional iGluRs was checked by electrophysiological measurements. When 
patched in whole cell configuration 46% of all measured G1702 cells showed currents upon 
application of 1 mM Glu and 100 µM Gly with a mean Imax of 42.7±14.7 pA, indicating functional 
iGluRs in primary GBM cells (Figure 16a). 
We next investigated the expression of NMDAR subunits by immunofluorescence staining. G1702 cells 
showed expression of GluN1 and GluN2B subunits. Consistently, GluN2B expression could be observed 
at the end of cellular protrusions (Figure 16b), indicating the same special distribution as in LN229 
cells (see Figure 8). 
Further, the colocalisation of Top2β and 53BP1 was checked in G1702 cells treated with 1 mM Glu 
overnight. As seen before in LN229 cells, immunofluorescence staining revealed that Top2β forms foci 
which partly colocalized with 53BP1 foci (Figure 16c and Figure 14a) suggesting Top2β is recruited 
to Glu-mediated DSBs in G1702 cells.  
 
  
Figure 16: NMDAR signaling in primary G1702 cells. (a) Whole cell patch clamp recordings of G1702 cells were performed by 
Juliane Joswig. Diagram shows the mean Imax of responsive cells after application of 1 mM Glu/100 µM Gly (error bars show 
SD). (b) Immunofluorescence staining of GluN1 and GluN2B subunits of the NMDAR in G1702 cells. Notably GluN2B subunits 
are localized at the end of cellular protrusions (GluN1/GluN2B=green, Hoechst33342=blue; scalebar: 25 µm). (c) 
Immunofluorescence staining of 53BP1 (red) and Top2β (green) in G1702 cells. Top2β and 53BP1 form foci which partly 
colocalize (scalebar 20 µm). (d) Relative cFos/GAPDH expression in G1702 cells treated with 1 mM Glu and 20 µM MK801, 
20 µM ifenprodil or 1 µM ICRF193 overnight and analyzed by western blot. NMDAR inhibition leads to a non-significant 
decrease of cFos expression while ICRF193 significantly decreases cFos expression (error bars show SD, n=3, One sample t-test, 
p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***)). 
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Finally, we analyzed the impact of NMDAR signaling on cFos expression. G1702 cells were treated 
with 1 mM Glu and NMDARs were inhibited with MK801 (20 µM) or the specific GluN2B inhibitor 
ifenprodil (20 µM) and cFos expression was quantified by western blot (Figure 16d). For MK801 
treatment we observed a mean cFos expression of 46±27% compared to Glu treated cells (p=0.075). 
The mean expression of cFos after ifenprodil treatment was 53±33% of the control (p=0.134). 
Although the mean expression of cFos indicates even stronger down regulation than in LN229 cells, 
high variances do not allow to state significant changes of cFos. In contrast, inhibition of Top2 with 
1 µM ICRF193 decreased the mean expression of cFos significantly to 37±3% in G1702 cells 
(p<0.001), underlining the importance of the Top2 on cFos expression in GBM cells. 
 
 
5.4.3. Top2β-dependent NMDAR signaling promotes radioresistance in LN229 cells   
 
Inhibition of Top2 endonuclease activity impacts the induction of NMDAR-mediated DSBs in LN229 
cells and reliably inhibits cFos expression in two GBM cell lines. In addition, immunofluorescence 
staining indicated that Top2β activity is involved in NMDAR signaling in GBM cells. In neurons, the 
activity of Top2β mediates NMDAR-dependent gene expression [104].  
To proof the specific role of Top2β for NMDAR signaling in GBM cells a knock down of Top2β with two 
different siRNAs was performed. Western blot analysis of siRNA transfected LN229 cells revealed that 
both siRNAs successfully down regulated Top2β (Figure 17a). Additionally, Top2β knock down 
significantly decreased the expression of cFos to about 50% compared to cells transfected without RNA 
(si1 55.7±8.2%, p=0.012; si2 53.6±6.1%; p=0.005). Remarkably, siRNA knock down of Top2β leads 
to a stronger decrease of cFos than inhibition of Top2 with ICRF193 (compare Figure 15a and Figure 
17a). Thus, the specific knock down of Top2β with siRNA confirms that cFos regulation in LN229 cells 
is dependent on Top2β activity. 
The discovery of NMDAR-dependent and Top2β-mediated regulation of cFos in GBM cells raises the 
question if inhibition of this pathway could be used as a therapeutic strategy for GBM patients. cFos 
overexpression has been correlated with radioresistance in GBM cells [98], suggesting that down 
regulation of cFos through inhibition of the NMDAR signaling pathway might sensitize GBM cell to 
irradiation. Therefore, clonogenic survival upon irradiation with X-rays was performed with and 
without siRNA knock down of Top2β. LN229 cells were transfected with one of two siRNAs (si1; si2) 
or without RNA (no siRNA) or kept untransfected (c) and all samples were additionally treated with 1 
mM Glu. All samples were irradiated with 0 Gy-6 Gy of X-rays and clonogenic survival was 
determined. The results show that there is no difference between control cells (c) and cells transfected 
without RNA (no siRNA) (Figure 17b). Knock down of Top2β with siRNA2 (si2, red) significantly 
decreased the clonogenic survival of LN229 cells already at 2 Gy (p=0.014), but also at 4 Gy (p=0.01) 
   46 
and 6 Gy (p=0.002) compared to transfection without siRNA. Transfection with siRNA1 led to a less 
pronounced decrease of the clonogenic survival and only shows a significant decrease at 6 Gy 
(p=0.035) (Figure 17b). However, in LN229 cells Top2β knock-down clearly decreases 
radioresistance. 
Induction of regulative DSBs by Top2β is a later event of the NMDAR signaling pathway. To validate 
the specific role of NMDAR signaling on radioresistance we decided to inhibit the initial step of the 
NMDAR signaling pathway with the GluN2B specific antagonist ifenprodil. For this, LN229 cells were 
treated with 1 mM Glu or 1 mM Glu/20 µM ifenprodil, irradiated with 0 Gy-6 Gy X-rays and 
clonogenic survival was determined. Inhibition of NMDAR with ifenprodil significantly decreases the 
clonogenic survival at 2 Gy (p=0.009), 4 Gy (p=0.009) and 6 Gy (p=0.02) (Figure 17c). The relative 
survival ratio for therapeutic dose of 2 Gy is 1.7 for ifenprodil treatment and 1.4 for siRNA2, indicating 
a similar potency of both treatments to decrease survival upon irradiation. Hence, inhibition of 
NMDAR signaling at two different steps sensitizes LN229 cells to X-ray treatment, confirming the 
impact of NMDAR activity for GBM radioresistance. 
 
 
Figure 17: Inhibition of NMDARs and siRNA knock down of Top2β sensitizes LN229 cells to X-ray treatment. (a) Successful 
knock-down of Top2β with two different siRNAs after overnight treatment with 1 mM Glu led to a significant down 
regulation of cFos. Relative cFos/GAPDH expression was analyzed by western blot (n=4; error bars show SD; One sample t-
test). (b) Clonogenic survival of LN229 cells treated with 1 mM Glu and transfected with two different siRNAs against Top2β 
or transfected without RNA and irradiated with 0, 2, 4 and 6 Gy X-ray. Diagram shows fitted data. siRNA2 significantly reduces 
the survival starting at 2 Gy. siRNA1 shows an intermediate effect (n=3, each experiment was performed as triplet; error bars 
show SD; student´s t-test). (c) Clonogenic survival of LN229 cells treated with 1 mM Glu or 1 mM Glu/20 µM ifenprodil and 
irradiated with 0, 2, 4 and 6 Gy X-ray. Diagram shows fitted data. Ifenprodil significantly reduces the survival starting at 2 Gy 
(n=3, each experiment was performed as triplet; error bars show SD; student´s t-test). (p>0.05 (ns), p≤0.05 (*), p≤0.01 (**), 
p≤0.001 (***)) 
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5.5. NMDAR signaling impacts IR activated gene expression in GBM cells 
 
IR activates CREB through phosphorylation at Ser133 in GBM cells and induces the expression of cFos 
in neurons [73, 138]. This raises the question if NMDAR signaling interplays the IR activated gene 
expression in GBM cells. We therefore decided to check the relations of NMDAR-dependent gene 
regulation and irradiation induced gene activation on the secretion of BDNF. At first, LN229 cells were 
treated without or with 250 µM SAS or additionally with 1 mM Glu and irradiated with 2 Gy X-rays or 
sham and all values were normalized to SAS treated cells. Since only one independent experiment was 
done it cannot be stated if differences are significant or not. If not treated with SAS, BDNF increased to 
134±16% compared to SAS treated samples and irradiation further increased the amount of BDNF to 
219±30% (Figure 18a). Interestingly, the amount of BDNF only increased to 106±7% upon 
irradiation when treated with SAS. Glu treatment increased BDNF to 127±7% and when samples were 
additionally irradiated BDNF further increased to 241±59%. Thus, Glu treated samples and control 
samples without SAS show a high secretion of BDNF upon irradiation while SAS treated samples did 
not.  
 
 
Figure 18: Impact of IR on BDNF and cFos expression upon NMDAR activation. (a) BDNF secretion in LN229 cells after 
treatment without or with 250 µM SAS and/or additionally 1 mM Glu, 1 mM Glu/20 µM MK801 or 1 mM Glu/25 µM KG501. 
The cells were irradiated with 2 Gy X-rays directly after treatment or sham irradiated and BDNF concentration in the media 
was measured next day with an antibody based assay kit. All values are normalized to SAS treated, sham irradiated cells. The 
lack of SAS or additional treatment with Glu caused a high increase of BDNF after irradiation while treatment with MK801 or 
KG501 blocked the increase of BDNF upon irradiation (n=1, bar diagrams show the mean value of triplets, error bars show 
SEM, no statistical test was done since n=1). (b) Radiation-induced cFos expression. LN229 cells were treated with 1 mM Glu or 
1 mM Glu/20 µM ifenprodil and irradiated with 2 Gy X-rays or sham. Next day the relative amount of cFos was measured by 
western blot. The graphs show the relative change of cFos expression after irradiation. cFos seems to be upregulated after 
irradiation when treated with Glu but inhibition of NMDARs with ifenprodil seems to negate radiation-induced cFos 
expression. All results are tendencies; no significant chances can be stated (p=4; student´s t-test; one sample t-test). 
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Additionally, we checked if Glu- and radiation-dependent regulation of BDNF is mediated by NMDAR 
signaling proteins. For this, LN229 cells were treated with 1 mM Glu/250 µM SAS and NMDARs or 
CREB were inhibited with 20 µM MK801 or with 25 µM KG501 respectively. MK801 decreased the 
amount of BDNF compared to Glu treatment (113±35%% to 127±7%) and irradiation notably failed 
to increase BDNF upon MK801 treatment (109±59%) indicating that NMDAR-activation is needed for 
radiation-induced BDNF expression. CREB inhibition decreased the amount of BDNF compared to Glu 
treatment as well (106±8% to 127±7%) and irradiation led to a minor increase of BDNF (135±16%) 
compared to Glu treatment (241±59%) confirming the role of NMDAR signaling on LN229 radiation 
response.  
To validate the role of NMDARs for radio response, the expression of cFos upon radiation and NMDAR 
inhibition was investigated. LN229 cells were treated with 1 mM Glu or 1 mM Glu/20 µM ifenprodil 
and irradiated with 2 Gy X-rays or sham irradiated. Figure 18b shows relative amount cFos in 
irradiated cell compared to sham irradiated cells. When treated with Glu the mean amount of cFos was 
increased to 125±15% after irradiation, while cells additionally treated with ifenprodil did not show 
an increase of cFos (102±9%) upon irradiation. However, neither the induction of cFos upon 
irradiation nor the reduction upon ifenprodil (p=0.23) treatment is statistically significant. 
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6. Discussion 
 
GBM, one of the most lethal cancers, is incurable due to its high heterogeneity, radioresistance and 
invasive growth [8, 9, 76]. GBM cells use autocrine secreted Glu to promote their growth, survival and 
invasion upon activation of Ca2+-permeable iGluRs [41]. The high Ca2+-conductance and impact 
among several cancers brought NMDARs into the focus of Glu-induced malignancy in GBM [48-50, 52, 
53]. Although the effects of NMDAR activation in GBM cells are well studied, the signaling pathways 
behind NMDAR-mediated survival and growth are unknown [50, 73, 75, 131]. We hypothesized that 
GBM cells use NMDAR-dependent regulation of ERGs analogous to neurons.  
NMDAR-dependent expression of ERGs is a hallmark for the development and plasticity of our brain 
and cognitive functions like learning and memory [33, 34, 64]. The expression of these genes, which 
are in part also implicated in tumor malignancy, is controlled by NMDAR activity triggered induction 
of DSBs within their promoter regions [98-100, 104, 105]. Here, we investigated whether this 
particular step of neuronal signaling, the NMDAR-dependent Top2β-induced DSBs, exists analogous in 
GBM and thus might be a new challenging aspect for cancer therapy. Our data reveal that beyond the 
basal function of NMDARs in excitatory neurotransmission and synaptic plasticity, these receptors play 
indeed a prominent role in the malignancy of human tumors. The presented results demonstrate the 
increased expression of ERGs upon NMDAR activation and the implication of these genes in mediating 
tumor survival and radioresistance.  
 
 
6.1. Role of spatial and temporal NMDAR-mediated Ca2+ transients in GBM physiology 
 
To investigate NMDAR signaling in GBM cells we used the LN229 GBM cell line and first validated 
expression of NMDARs as well as Glu-mediated Ca2+ conductance (Figure 8).  
Activation of NMDARs by Glu and subsequent channel opening and Ca2+-influx are the initial steps of 
NMDAR signaling in neurons [79]. In LN229 cells, application of Glu/Gly transiently increased the 
intensity of the Ca2+ sensitive dye Fluo-4 in cell protrusions demonstrating Ca2+ transients through the 
membrane. The increase of intracellular Ca2+ showed a cell compartment specific kinetic, the nuclear 
area reveals a slow Ca2+ oscillation with high amplitudes while the faster Ca2+ oscillations with lower 
amplitudes were observed in the cellular protrusions (Figure 8a/b). 
Immunofluorescence staining of the NMDAR subunits showed that GluN1, GluN2A and GluN2B were 
expressed along the membrane and especially in cell protrusions. The accumulation of NMDAR 
subunits inside the membrane of protrusions indicates a specialized localization of NMDAR in the 
membrane likely through binding of intracellular proteins (Figure 8c). The Glu/Gly-mediated Ca2+ 
transients in the cell protrusions fit the localization of NMDAR subunits observed in 
immunofluorescence staining, which suggests functional NMDARs in LN229 cells.  
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In neurons the binding of NMDARs to proteins of the postsynaptic density are crucial for functional 
NMDAR signaling [75, 79]. The specific localization of NMDARs suggests that NMDAR binding 
proteins might also be present in LN229 cells.  
Local Ca2+ pules control lamellipodia retraction in migrating cells [139] and NMDAR-mediated Ca2+ 
oscillation promote neuronal migration upon CaMKII activation [90, 140]. The finding, that Glu/Gly 
induces local Ca2+ transients within lamellipodia of LN229 cells, fits to the observation that NMDARs 
promote migration in GBM cells [50, 73, 75] and suggest that migration is similar regulated in GBM 
cells and neurons. 
NMDAR-mediated Ca2+ oscillation also control gene expression [141]. As shown, Glu/Gly treatment 
increased the intensity of Flou-4 inside the nuclear area (Figure 8b), which is likely caused by 
increased nuclear Ca2+ concentrations. Nuclear Ca2+ is a main mediator of NMDAR-dependent gene 
expression through activation of nuclear CaMKIV and CREB [61, 142]. Hence, Glu-mediated increase 
of nuclear Ca2+ in LN229 cells further suggests functional NMDAR signaling similar to neurons. 
50% of the tested LN229 cells responded to Glu/Gly treatment with increased nuclear Ca2+. Hence, 
Glu-mediated Ca2+ signaling is no uniform property of LN229 cells but occurs in a subpopulation of 
cells (Figure 8a), representing GBMs heterogenic nature [8]. The observation, that only a 
subpopulation of LN229 cells responded to Glu/Gly during Ca2+-imaging, fits the results from 
electrophysiological measurements of LN229 cells, where Glu/Gly-induced currents in ~40% of all 
cells and is also supported by the finding that GBM tumors do not show homogeneous NMDAR-
expression in vivo [50, 73]. 
Repeated Ca2+ influx does not cause an overall increase of cytoplasmic Ca2+ in LN229 cells (Figure 
8b), which would be an initial mediator of excitotoxic apoptosis in neurons [77, 78]. The lack of 
cytoplasmic Ca2+ increase therefore confirms the non-toxic role of NMDARs in GBM cells [50, 73]. 
In sum, NMDAR expression and Glu-mediated Ca2+ transients at cell protrusions and lamellipodia as 
well as increased Ca2+ concentration in the nuclear area of LN229 cells indicate functional NMDAR 
signaling, similar to neurons. Thus, LN229 cells are a suitable cell system to investigate NMDAR 
signaling in GBM cells. 
 
 
6.2. NMDAR activation induces DSBs in a GBM subpopulation 
 
As described in chapter 3.3., the induction of DSBs into the TSS of ERGs is required for the activity-
dependent expression of these genes in neurons [104]. To verify if NMDAR-mediated DSB induction is 
also present in GBM cells, we quantified 53BP1 foci in LN229 cells with and without Glu treatment. 
53BP1 is a DNA repair protein, which accumulates at DSB site during DNA damage response and is a 
broadly used DSB marker which may persist after DSB repair [143]. 
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Inhibition of Glu release via system X-c with SAS led to relatively low numbers of 53BP1 foci, while 
simulations treatment with Glu revealed significantly more 53BP1 foci in LN229 cells. Together with 
the rapid disappearance of 53BP1 foci already 30 min after Glu depletion, these results demonstrate 
Glu specific induction of 53BP1 foci in LN229 cells (Figure 9a). We could verify that the 53BP1 foci 
indeed represent DSBs by inhibiting the NHEJ DNA repair pathway (Figure 9b). Inhibition of DNA-
PKcs with NU7441 prevented the fast disappearance of 53BP1 foci upon Glu depletion. This clearly 
demonstrates that 53BP1 foci represent DSBs induced by Glu, which are rapidly repaired via DNA-PKcs-
dependent NHEJ. 
DNA-PKcs inhibition led to a prolonged activation of neuronal genes which are regulated via DSB 
induction and has been proposed to facilitate the repair of Glu-induced DSBs in neurons [104]. 
Furthermore, DNA-PK has been closely linked to DSB-regulated transcription in other cells [122, 123]. 
Unlike to neurons, in MCF-7 breast cancer cells DNA-PKcs activity is supposed to be needed for the 
induction of regulatory DSBs rather than for repair. Pre-incubation with NU7441 prevents estrogen 
receptor α dependent induction of γH2AX foci in MCF-7 cells, indicating a role of DNA-PKcs in the 
induction of DSBs or at least in the phosphorylation of γH2AX [123]. In LN229 cells, overnight 
treatment with NU7441 and Glu significantly increased the number of 53BP1 foci compared to Glu 
treatment alone (Figure 9b). Hence, the results from LN229 cells are comparable to the results found 
in neurons, where DNA-PKcs mediates the repair of Glu-dependent DSBs. 
 
Individual LN229 cells differently responded to Glu treatment with the induction of DSBs. While some 
cells had high numbers 53BP1 foci, other cells showed no or few foci (Figure 10a). To estimate how 
the number of DSBs is distributed among LN229 cells, we performed a high-content automatic 
quantification of 53BP1 foci, which confirmed the Glu-dependent induction of DSBs in LN229 cells 
(Figure 10b). The histogram of the 53BP1 foci/cell number shows a general shift from low numbers of 
foci in SAS treated cells to higher numbers of foci in SAS/Glu treated cells (Figure 10c). In neurons, 
NMDAR-dependent induction of DSBs was identified within 20 genes [104], suggesting that Glu 
induces DSBs in a specific number of genes in LN229 cell as well, which might be displayed by a 
specific number of 53BP1 foci. The histogram indicates a small peak at 10 foci/cell but the limited 
sample size does not allow a statistical validation of this increase (Figure 10c). 
The separation of LN229 cells into three classes bearing no, one to three or more than three 53BP1 
foci/cell revealed that the percentage of LN229 cells without 53BP1 foci decreases from 81.4% to 
45.4% upon Glu treatment, indicating that at least 36% of all LN229 cells reacted to Glu with the 
induction of DSBs (Figure 9d). Most responding cells showed a low increase of 53BP1 foci (20 percent 
of all cells) but 16% of all cells also displayed a high increase of 53BP1 foci after Glu treatment 
(Figure 9d), indicating similar induction of high and low number of DSBs in LN229 cells. Hence, 
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53BP1 foci counting did not reveal any preference in the number of Glu-induced DSBs in LN229 GBM 
cells. 
The finding that at least 36% of all LN229 cells did and 45.4% did not respond to Glu treatment with 
the induction of 53BP1 foci (Figure 9d) is in line with the inhomogeneous expression of iGluRs in the 
LN229 cell population. Interestingly, the fraction of cells which respond to Glu with the induction of 
DSBs fairly matches the percentages of Glu/Gly responsive LN229 cells in Fluo-4 imaging (50%) 
(Figure 8) and in electrophysiological measurements (~40%) [73]. This suggests that LN229 cells 
expressing functional iGluRs also respond to Glu with the induction of DSBs. 
The seemingly random induction of 53BP1 foci upon Glu treatment may be caused by a high variance 
(Figure 10c). During the catalytic cycle Top2β-mediated DSBs are normally religated after T-segment 
transition (Figure 6) without activation of DNA damage response proteins [110]. Top2β-induced DSBs 
should therefore be undetectable by DSBs markers like 53BP1 and γH2AX. Nevertheless, Top2β activity 
has been shown to induce γH2AX and 53BP1 foci in order to start transcription [104, 122, 123]. The 
reason for this atypical functioning is not understood. Pommier et al. proposed that long-lived 
transcriptional DSBs might be induced stochastically upon Top2β activity or may depend on temporary 
blockage of Top2β religation for example through acute tensions within the G-segment [106, 109]. In 
consequence only a part of Top2β-induced DSBs are long-lived enough to induce DNA damage 
response which can be detected with DSB markers. This idea is also supported by the results of 
Madabhushi and colleges in 2015. They demonstrated that phosphorylation of H2AX results from 
Top2β-mediated DSB induction in at least 20 genes, but the number of γH2AX foci in NMDA treated 
neurons was below that number, the shift between the induced DSBs and the number in foci indicates 
that Top2β-induced DSBs do not necessarily provoke a detectable DNA damage response [104].  
The stochastic variation of the detectable DSBs might provide a reason for the highly variable number 
of 53BP1 foci observed upon Glu treatment in LN229 cells. In addition, the overnight treatment with 
Glu likely leads to repeated induction and repair of Glu-induced DSBs. As a result, the analysis of 
53BP1 foci includes cells which are in different stages of DSB induction and repair, leading to highly 
variant 53BP1 foci number. Following these thoughts, the actual amount of Glu-induced DSBs cannot 
be detected in most cells, while the rest of the cells show lower numbers of 53BP1 foci. Interestingly, 
all numbers of 53BP1 foci/cell between 0-20 could be observed in LN229 cells while only four out of 
1514 cells showed more than 20 53BP1 foci. In analogy with the results observed in neurons, this may 
hint that NMDARs also promotes the expression of up to 20 genes upon DSB induction in LN229 cells 
[104].  
Anyhow, counting DSB markers like 53BP1 and γH2AX is no reliable way to determine the total 
number of DSBs induced by Glu. DSB markers can be used to analyze the overall increase in DSBs and 
therefore are a useful tool to analyze Glu-induced DSBs. To analyze how many and where Glu-
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dependent DSBs are induced in GBM cells other methods like chromatin immunoprecipitation DNA-
sequencing (Chip-Seq) of γH2AX [104] should be used. 
Activation of synaptic iGluRs upon neuronal activity leads to the induction of regulatory DSBs in 
neurons and NMDAR-dependent Ca2+ currents have been shown to mediate the DSB induction [104]. 
In GBM cells Ca2+ permeable AMPARs and NMDARs have been shown to impact cell survival and 
migration [40, 46, 144]. Since LN229 cells functionally express NMDARs and AMPARs [144] we 
analyzed the contribution of NMDAR and AMPAR activation to the induction of DSBs in LN229 cells. 
NMDARs activation induced the same number of 53BP1 foci as Glu, while activation of AMPARs led to 
a decreased number of foci (Figure 11a). Similar, inhibition of NMDARs with ifenprodil led to 
stronger decrease of 53BP1 foci in Glu treated LN229 cells than inhibition of AMPARs with NBQX 
(Figure 11a). Taken together, activation and inhibition of NMDARs and AMPARs clearly show that 
Glu-dependent DSBs are mainly mediated by NMDARs in LN229 cells. 
However, AMPAR activation increased the number of 53BP1 foci/cell as well, indicating that AMPARs 
are capable to induce DSBs in LN229 cells. Similar to NMDARs, AMPARs bind to synaptic scaffold 
proteins, leading to a colocalization of AMPARs and NMDARs in neurons [145]. This suggests that 
AMPARs and NMDARs colocalize in LN229 cells as well. In contrast to most neuronal AMPARs, those 
AMAPRs expressed in GBM cells have been reported to be permeable for Ca2+ [45, 46]. This specific 
Ca2+ permeability and the putative colocalization with NMDARs might enable AMPARs to activate 
typical NMDAR-dependent signaling pathways, like the induction of DSBs, in GBM cells. 
However, NMDARs have been identified to be the main mediator of Glu-dependent DSBs in LN229 
cells. In addition to LN229 cells, NMDARs also mediate Glu-dependent induction of DSBs in the GBM 
cell line U-87 MG, which has been shown to express functional NMDARs [73]. Notably, NMDA 
treatment induced more 53BP1 foci than Glu treatment in U-87 MG cells (Figure 11b). LN229 cells 
and U-87 MG cells both secrete Glu via system X-c [40, 144] which has been inhibited during the 
experiments with SAS. But unlike other GBM cells lines [36] U-87 MG cells express the Glu transporter 
EAAT2, which imports extracellular Glu [146]. Combined system X-c inhibition and EAAT2 expression 
might lead to a continuous decrease of extracellular Glu but not NMDA in the media of U-87 MG cells 
during the experiments. The lower Glu concentration could lead to a partial activation of iGluRs and a 
decreased response. In contrast, LN229 cells showed slow increase of extracellular Glu even with SAS 
treatment, indicating no Glu uptake via EAAT2 [73]. 
The NMDAR blocker MK801 significantly reduced the number of 53BP1 foci in Glu treated U-87 MG, 
while specific inhibition of GluN2B bearing NMDARs with ifenprodil showed no significant reduction 
of 53BP1 foci (Figure 11b). The mean values of 53BP1 foci/cell were 1.8±0.2 for MK801 and 1.9±0.2 
for ifenprodil treated U-87 MG cells, suggesting that an increased sample size might resolve the 
statistical insignificance of the ifenprodil treatment. The almost equal potency of ifenprodil and MK801 
to reducing Glu included DSB suggests that even most NMDARs which contribute to DSB induction 
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contain GluN2B subunits. Combined with the distinct effect of ifenprodil in LN229 cells (Figure 11a), 
these results confirm the explicit role of GluN2B in NMDAR signaling of GBM cells which has been 
proposed in previous studies [50, 73].  
In sum, we could identify Glu-mediated DSBs in a subpopulation of GBM cells. These DSBs depend on 
NMDAR activation and are repaired by NHEJ, which points out that the induction and repair of Glu-
mediated DSBs in GBM cells is equally regulated as in neurons [104]. 
 
 
6.3. NMDAR-dependent DSBs are associated with Top2β activity 
 
To address the question how Glu-dependent DSBs are induced in GBM cells, we analyzed the role of 
cell cycle progression of NMDAR-mediated DSBs. Replicational stress leads to the induction of DSBs 
during S-phase and some of these breaks remain unrepaired during cell cycle progression, leading to a 
higher number of DSBs in G2-phase cells than in G1-phase cells [147]. Since Glu-induced DSBs have 
been counted in G1- and G2-phase cells, a shift of the G1 to G2 ratio would also shift the determined 
mean of 53BP1 foci/cell. 
Analysis of 53BP1 foci shows that Glu and NMDA induce DSBs in G1-phase cells, indicating that Glu-
dependent induction of DSBs is independent of cell cycle progression (Figure 12a). Additionally, the 
EdU cell cycle assay revealed that Glu and NMDA treatment do not alter cell cycle progression of 
LN229 cells (Figure 12b), clearly demonstrating that DSB induction upon NMDAR activation is not 
caused by cell cycle distortions. 
Glu-dependent DSBs are required to start the transcription of ERGs in neurons [104]. We expected 
Glu-induced DSBs to regulate gene expression in LN229 cells as well and transcriptional activity is 
highest during G1-phase [134, 135]. Thus, Glu-dependent DSB induction in G1-phase cells supports 
the idea of a transcriptional role of Glu-induced DSBs in LN229 cells. The Glu-dependent induction of 
DSBs in G1- phase cells, might additionally hint that Glu-induced DSBs are mediated by Top2β, since 
Top2α has been shown to be mainly expressed during S- and G2-phase, while Top2β is constantly 
expressed during all cell cycle phases [109, 118]. 
In neurons, NMDAR-dependent induction of DSBs is mediated by Top2β. Catalytic inhibition of Top2 
with ICRF193 and simulations Glu treatment did not significantly decrease the number of 53BP1 foci 
in LN229 cells compared to Glu treated cells but reached almost the exact value of MK801 treated 
LN229 cells (Figure 13), suggesting that Top2 inhibition would reveal a significant reduction of 53BP1 
foci upon repeated testing. Double treatment with MK801 and ICRF193 did lead to a slight and non-
significant decrease which indicates a sub-additive effect of NMDAR and Top2 inhibition and suggests 
that NMDAR and Top2 are part of the same signaling pathway (Figure 13). 
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Our results show that Top2 activity likely induces NMDAR-dependent DSBs in LN229 cells, but it is not 
clear which Top2 isotype is responsible for the induction. ICRF193 has been reported to be more 
potent against Top2β than Top2α [148] and to avoid Top2 poisoning only 100 nM ICRF193 were used, 
suggesting a predominant inhibition of Top2β. However, a higher sensitivity of Top2α to ICRF193 has 
been reported as well, forbidding to state a specific inhibition [149].  
 
In expectation that Top2β mediates Glu-induced of LN229 cells, we performed a immunofluorescence 
staining against Top2β, which revealed a focal accumulation of Top2β as well as colocalization with 
53BP1 foci, indicating high Top2β activity at DSB sites (Figure 14a). Glu treatment significantly 
increased the number of Top2β foci in LN229 cells to a similar extent as 53BP1 foci (Figure 14b).  
The increased number of Top2β foci upon Glu treatment suggests that Top2β is activated by Glu in 
LN229 cells. The colocalization of Top2β and 53BP1 as well as the simultaneous increase in Top2β and 
53BP1 foci points out that increased Top2β activity correlates with DSBs induction in LN229 cells.  
Top2β activity promotes the induction of DSBs in neurons [104] but Top2β has also been implicated in 
DNA damage repair of GBM cells [150], indicating that Top2β foci are the consequence of DSB 
induction rather than their cause. The reduced number of DSBs upon ICRF193 treatment (Figure 13) 
shows that Top2β is not involved in the repair of Glu-induced DSBs in LN229 cells, since a decreased 
Top2β-mediated repair upon ICRF193 treatment should lead to an increased number of DSBs.  
Taken together, decreased DSB induction upon Top2 inhibition and induction of Top2β foci upon Glu 
treatment demonstrate that Top2β activity likely induces Glu-dependent DSBs in LN229 cells. The 
Top2β-dependent induction of DSBs suggests that LN229 cells use the same NMDAR signaling 
pathway, which regulates the expression of ERGs in neurons [104]. 
 
 
6.4. Implications of NMDAR-mediated DSB formation for the expression of ERGs 
 
We checked if Top2-mediated NMADR signaling is indeed capable to promote transcription of the ERG 
cFos in LN229 cells (Figure 15). The results show, that cFos expression is downregulated upon 
inhibition of NMDARs with ifenprodil as well as inhibition of CREB with KG501 and Top2 with 
ICRF193 (Figure 15a). The decreased cFos expression upon inhibition of three different proteins in 
the NMDAR signaling pathway clearly demonstrate that cFos is regulated upon NMDAR activation in 
LN229 cells. The Top2 dependence of cFos expression in particular shows that cFos expression is 
mediated by the induction of regulatory DSBs, and therefore shows that NMDAR signaling in neurons 
and GBM cells both use the induction of DSBs to promote gene transcription of cFos.  
Notably, the simultaneous inhibition of NMDARs with MK801 and AMAPRs with NBQX did not lead to 
a significant decrease of cFos but showed highly variant results (Figure 15a). MK801 should at least 
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have the same effect as ifenprodil since MK801 blocks all NMDARs. According to Choo et al., the 
differential activation of signaling pathways by NMDARs with different subunit compositions might be 
one reason for the different effects of MK801 and ifenprodil on cFos expression [84]. Another reason 
for the high variability of MK801 provides the fact that MK801 is quite unstable under cell culture 
conditions, with a half-life of ~1 h [151]. We used 20 µM MK801, which should be sufficient to fully 
block NMDARs, but rapid degradation might result in a minor or even no block. The need for high 
MK801 concentrations is also demonstrated by other publications where up to 700 µM MK801 were 
used [53]. However, ifenprodil treatment reliably inhibited cFos expression demonstrated the impact 
of NMDARs on cFos expression and confirmed the important role of GluN2B for GBM cells at the same 
time [50]. 
NMDAR and Top2β inhibition caused a similar decrease of cFos expression but CREB inhibition lead to 
a stronger downregulation of cFos (Figure 15a). Phosphorylation of CREB at Ser 133 upon Glu 
treatment was demonstrated by Müller-Längle et al. [73], but CREB phosphorylation is promoted by 
many other factors including growth factor FGF-2 and neurotrophins [88, 152]. This suggests that 
CREB inhibition interferes with additional pathways which regulate CREB-dependent cFos expression 
in LN229 cells. In turn, the similar inhibition of cFos by ifenprodil and ICRF193 suggest that Top2β 
does not regulate cFos expression beside the NMDAR signaling pathway. 
The transcription factor cFos is known to be important for brain development [153] and also a proto-
oncogene [100, 105]. In order to estimate the impact of impaired cFos expression we analyzed the 
expression of BDNF, a gene which is regulated by cFos [154] and also is a prominent promoter of 
glioma growth [13, 15, 137, 155]. 
Our results show that BDNF secretion of LN229 cells increases upon Glu treatment (Figure 15b). The 
inhibition of NMDARs with MK801 revealed a non-significant (p=0.07) decrease, while CREB 
inhibition led to a stronger and significant downregulation of BDNF. Additionally, inhibition of 
catalytic activity of Top2 with merbarone results in downregulation of BDNF, indicated by a single 
experiment.  
Although the decrease of BDNF secretion upon MK801 treatment is not significant, the result (n=2) 
indicates that additional data may show a significant decrease. In analogy to cFos expression, 
inhibition of CREB shows the strongest decrease of BDNF secretion. BDNF is regulated by nine 
promoter and various transcription factors, beside others also directly by CREB [156]. This might 
suggest that BDNF expression is not regulated by cFos in LN229 cells at all, but directly by NMDAR-
mediated CREB activation. However, the downregulation of BDNF by merbarone indicates a cFos-
dependent regulation of BDNF in LN229 cells. Madabhushi and colleges demonstrated that Top2β 
regulates the expression of cFos and explicitly showed that Top2β does not regulate the expression of 
BDNF [104], indicating that merbarone-mediated downregulation of BDNF depends on cFos. 
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In summary our results revealed functional NMDAR signaling in LN229 cells, which is capable to 
regulate gene expression. The Top2-dependent expression of cFos shows that LN229 cells use the 
induction of regulatory DSBs to promote the expression of an ERG, which demonstrates that LN229 
cells use the same regulatory pathway for ERG expression as neurons [104]. Furthermore, the 
NMDAR-dependent expression of cFos and BDNF demonstrates that NMDAR signaling may have high 
impact on the malignancy of GBM cells, since cFos and BDNF promote radioresistance and tumor 
growth and have been shown to correlate with poor prognosis in glioma [13, 15, 98, 137, 155].  
 
The investigation of NMDAR signaling in LN229 cells revealed the impact of NMDAR-dependent and 
Top2β-mediated induction of DSBs. We used the primary GBM cell line G1702, which was grown as 
spheroid culture, to check if our findings in GBM cell lines also reflect the situation in primary GBM. 
Whole cell patch clamp recording showed Glu/Gly-induced currents in 46% of the cells, demonstrating 
functional iGluR expression (Figure 16a). Immunofluorescence staining of GluN1 and GluN2B 
revealed a similar localization pattern as in LN229 cells (Figure 16b and Figure 8c), indicating similar 
binding to intracellular proteins and therefore similar signaling. In additional analogy to LN229 cells, 
G1702 cells show Glu-induced 53BP1 foci which colocalize with Top2β foci, indicating Top2β-
mediated induction of DSBs (Figure 16c and Figure 14a). Last, NMDAR inhibition with MK801 and 
ifenprodil led to a highly variable and therefore non-significant decrease of cFos, while inhibition of 
Top2β significantly decreased the expression of cFos in G1702 cells (Figure 16d). 
These results demonstrate that the primary GBM cell line G1702 shows similar signaling properties as 
LN229 cells. The expression of iGluR in 46% of all G1702 cell and 40% of all LN229 cells [73], the 
similar expression of NMDAR subunits and the colocalization of 53BP1 and Top2β foci upon Glu 
treatment demonstrate a similar subpopulation of Glu responsive cells in both cell lines. However, the 
observation of patch clamp recording and immunofluorescence staining might not fully reflect the 
situation of the spheroid culture since G1702 cells were grown as adherent cultures on laminin for 
these experiments.  
The analysis of cFos expression in G1702 cells revealed a similar high variance upon MK801 treatment 
as in LN229 cells, which might as well be caused be the relative instability of MK801 [151]. 
Unexpectedly, in G1702 cell ifenprodil treatment led to a similar high variance in cFos expression as 
MK801, suggesting variant expression of GluN2B containing NMDARs. Interestingly, in tumor samples 
high GluN2B expression has been shown at the tumor margin but not inside the tumor mass [50], 
suggesting that the relative number of GluN2B expression cells changes with the size of the tumor. 
This observation might also be true for spheroid cultures. If GluN2B expression is restricted to the edge 
of the spheroid, the spheroid size would determine the percentage of GluN2B-expressing cells. For our 
experiments we did not use spheroids of controlled size, which might have led to the high variances in 
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the percentage of GluN2B-expressing cells and consequently in cFos expression upon ifenprodil 
treatment. 
Despite the high variances, both NMDAR inhibitors show the potency to reduce cFos expression in 
G1702 even more than in LN229 cells. This is also supported by the fact, that Top2 inhibition 
decreases cFos expression to 37% in G1702 compared to 80% in LN229 cells (Figure 15a and Figure 
16d). Interestingly, Top2 inhibition leads to a very reliable reduction of cFos expression with might 
indicate that NMDARs signaling can be effectively shut down upon Top2 inhibition in G1702 cells, 
although the results cannot exclude that Top2 activity might regulate cFos expression through 
additional pathways.  
Taken together, the primary G1702 cell line reveals several properties of functional NMDAR signaling, 
which shows a high potential in the regulation of cFos expression in this cells.  This demonstrates 
together with our results from LN229 and U-87 MG cells that NMDAR signaling might be broadly used 
among GBMs. Additionally the results confirm the potential benefit of Top2 inhibition in order to 
control cFos expression in GBM therapy.  
 
GBM cells use Top2β-dependent NMDAR signaling to regulate genes which have been shown to 
promote GBM growth, survival and radioresistance [13, 15, 98, 137, 155]. Especially inhibition of 
Top2 has been shown reliably decrease the expression of cFos in LN229 and G1702 cells. We therefore 
tested if Top2 inhibition can be used to impair NMDAR-mediated survival in GBM cells [73]. First we 
assured that impaired cFos expression upon ICRF193 treatment actually depends on the inhibition of 
Top2β. The specific knock-down of Top2β with two different siRNAs significantly reduces cFos 
expression in LN229 cells (Figure 17a), demonstrating Top2β specific cFos regulation. To validate the 
impact of Top2β-mediated gene expression the clonogenic survival of LN229 cells with Top2β knock-
down were irradiated with increasing doses of X-rays (Figure 17b). Top2β siRNA2 significantly 
decreased the clonogenic survival of LN229 cells already at 2 Gy while siRNA1 shows a lower decrease 
of clonogenic survival which still was significant at 6 Gy. This clearly shows that Top2β expression 
promotes radioresistance in LN229 cells. Interestingly, inhibition of NMDARs with ifenprodil reduced 
the clonogenic survival of LN229 cells to a similar extent as Top2β inhibition, with a relative survival 
ratio of 1.7 for ifenprodil treatment and 1.4 for siRNA2 for the therapeutic dose of 2 Gy (Figure 17c). 
The different radiosensitizing of siRNA1 and siRNA2 is surprising, since both siRNA similarly reduced 
the expression of cFos. The effectiveness of the siRNA to reduce the cologenic survival strongly 
depends on the transfection efficiency. siRNA1 already showed a higher variance in the reduction of 
cFos (Figure 17a), maybe caused by slow RNA degradation, and the lower transfection efficiency 
subsequently resulted in a reduced effect during the cologenic survival assay.  
The limited effectiveness of siRNA knock-down might also provide a reason why Top2β knock-down 
was slightly less effective to reduce the radioresistance in LN229 cells than ifenprodil treatment. 
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Additionally, NMDAR activation led to a faster repair of DSBs upon IR [73] which might also 
contribute to the radiosensitizing effect of NMDAR inhibition and suggests that NMDARs operates 
through additional pathways as the Top2β-mediated induction of ERGs in GBM cells. 
The striking effect of GluN2B specific inhibition with ifenprodil on NMDAR-dependent induction of 
DSBs and cFos expression as well as its radiosensitizing effect demonstrates the GluN2B containing 
NMDARs play an outstanding role in Glu-mediated gene expression and radioresistance of GBM cells. 
Together with the finding that GluN2B promotes the migration and invasion of GBM cells, our results 
show that GluN2B-expressing subpopulations promote GBM malignancy [50, 73, 75]. The highly 
invasive growth and radioresistance are challenging GBM therapy and inhibition of GluN2B therefore 
might provide a promising enhancement to current GBM therapies.  
 
 
6.5. IR enhances NMDAR signaling in GBM cells 
 
Adriana Längle demonstrates in her PhD thesis that both, NMDAR activation and IR phosphorylate 
CREB at Ser133 in LN229 cells and proposed an interplay of NMDAR signaling and IR damage 
response [144]. Interestingly, cFos expression is also promoted upon IR in the brain [138], suggesting 
that IR might promote the expression of genes which are regulated by NMDAR signaling. To 
investigate a potential interplay the secretion of BDNF upon radiation and NMDAR activation was 
measured in a single experiment (Figure 18a). IR increased the amount of BDNF only upon 
simultaneous Glu treatment but not upon inhibition of NMDARs or CREB. Although no statistical test 
could be performed these results indicate the NMDAR-mediated activation of CREB increases IR 
activated gene expression and therefore confirm the idea of a NMDAR-IR interplay. Further, IR 
potentially increases the expression of cFos upon Glu treatment, which is negated by simultaneous 
block of NMDARs with ifenprodil (Figure 18b).  
These results support the idea of NMDAR- and IR signaling interplay and suggest that NMDAR-
mediated radioresistance in GBM cells is enhanced by the link of NMDAR- and IR signaling pathways 
[73] (Figure 17b/c). 
In fact Adriana Längle suggested that in addition to phosphorylation of CREB at Ser133, IR might lead 
to phosphorylation of Thr100, Ser111 and Ser121, which deactivate CREB and reduce CREB-
dependent transcription [144]. In contrast, our results suppose an amplifying effect of IR on NMDAR-
mediated transcription. IR can activate MAPK pathways including the ERK1/2 signaling pathway 
[157]. IR generated reactive oxygen species are known to participate in ERK1/2 activation [158]. In 
addition, IR promoted the secretion of TGFα in A431 squamous carcinoma cells and MDA-MB-231 
mammary carcinoma cells, which induced EGFR-dependent ERK1/2 activation and increased the cells 
survival and proliferation [159].  
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However, ERK1/2 activation alone does not promote CREB-dependent gene transcription in neurons 
[160]. As described in Figure 4a, different signaling pathways contribute to the activation of NMDAR-
mediated gene transcription. NMDAR-dependent activation of ERK1/2 needs the increase of cytosolic 
Ca2+ near NMDARs to phosphorylate CREB at Ser133 [86]. Although phosphorylation of CREB at 
Ser133 is a commonly used marker for CREB activation it is not sufficient to activate CREB-mediated 
gene transcription [152]. To fully activate NMDAR-mediated gene expression the increase of nuclear 
Ca2+ is needed [141, 142]. Chawla and colleges demonstrated, that increased nuclear Ca2+ mediates 
CaMKIV-dependent phosphorylation of the CREB cofactor CBP at Ser301, which activates CBP and 
promotes transcription [160]. While nuclear Ca2+ increase is sufficient to promote CREB-mediated 
transcription, activation of ERK1/2 has been shown to enhance CREB-mediated transcription [160] 
and is thought to be needed for sustained CREB-mediated transcription upon NMDAR activation [86]. 
The enhancing effect of ERK1/2 activation on NMDAR-mediated gene transcription suggests that 
strong IR-mediated ERK1/2 activation might lead to the increased expression of cFos and BDNF upon 
NMDAR activation in GBM cells. In turn, ERK1/2 activation upon IR cannot promote cFos expression, 
because CBP is not activated through the increase of nuclear Ca2+. Interestingly, Ca2+ increases the 
catalytic activity of Top2β [161], suggesting that NMDAR-mediated increase of nuclear calcium might 
directly contribute to Top2β activation. 
The synergy of IR and NMDAR activation on the transcription of cFos and BDNF may explain the high 
impact of NMDAR signaling on GBM radioresistance and provides further evidence that inhibition of 
NMDAR signaling is a potential target for adjuvant radiotherapy. 
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7. Conclusion 
 
The results presented in this work demonstrate that GBM cells use Top2β-dependent NMDAR signaling 
to promote the transcription of the ERG cFos resulting in increased radioresistance. Based on our 
findings and results from other groups [40, 73] we propose how Glu mediates ERG expression in GBM 
cells (Figure 19). Glu secreted via system X-c activates NMDARs in GBM cells, which leads to Ca
2+ 
transients over the membrane and increases free nuclear Ca2+. While local Ca2+ increase at the 
membrane activates the ERK1/2 pathway, the nuclear Ca2+ increase activates CaMKIV which both lead 
to phosphorylation of CREB at Ser133. Additionally, CBP is activated by CaMKIV and Top2β gets 
activated either through not identified kinases or directly by increased Ca2+ concentration inside the 
nucleus. Top2β then induces a DSB in the promoter region of cFos allowing enhancer and promoter 
interaction. Together, Top2β-mediated DSB induction and phosphorylation of CREB and CBP initiate 
transcription of cFos and subsequently BDNF, which promote survival and radioresistance. 
 
 
Figure 19: Schematic model of NMDAR-mediated ERG transcription in GBM cells. Glu secreted by system X-c accumulates and 
activates NMDARs in the lamellipodia and cell protrusions of GBM cells. NMDAR channel opening allows Ca2+ transients lead 
to the activation of ERK1/2 and increase free nuclear Ca2+, likely released by intracellular Ca2+ stores. ERK1/2 facilitates the 
phosphorylation of CREB at Ser133. The increased nuclear Ca2+ allows CaMKIV to phosphorylate CREB and CBP at Ser133 and 
Ser301 and increases Top2β catalytic activity. Additionally, Top2β may be activated by nuclear Ca2+ and/or unknown kinases. 
Upon activation, Top2β inflicts a single DSB into the TSS of the cFos gene, which enables promoter-enhancer interaction. This 
interaction, together with CREB and CBP activation, allows the pausing Pol II to start transcription. cFos promotes the 
expression of BDNF and both, cFos and BDNF, promote survival and radioresistance in GBM cells. 
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The identification of Top2β-mediated, regulatory DSBs upon NMDAR activation show that GBM cells 
use a neuronal signaling pathway in order to promote their own survival and radioresistance [104]. 
Further, the usage of similar signaling pathways of GBM cells and neurons demonstrate that efficient 
NMDAR-mediated transcription of ERGs does not need the highly complex architecture of synapses. 
This indicates that limited requirements are needed for functional NMDAR signaling, although NMDAR 
signaling in neurons may be more complex, allowing fine-tuning of the NMDAR response during 
synaptic transmission [79]. 
NMDARs are expressed among several cancer types, which use NMDARs to promote survival and 
growth [52-54, 72, 89]. Additionally, Top2β-mediated gene expression is also used by different cancer 
cell lines upon activation of estrogen and androgen receptors [117], which suggests that other cancer 
types than GBM may meet the requirements for NMDAR-dependent and Top2β-mediated gene 
transcription. Thus, the mechanism identified by us in GBM cells, might also promote radioresistance 
in other NMDAR-expressing cancer cells.  
We also found, that NMDAR expression and NMDAR-mediated induction of DSB is no uniform 
property of GBM cells, but occur in a subpopulation of cells. Interestingly, high expression of Ca2+ 
permeable iGluRs and Top2β has been demonstrated in GBM TICs [150, 162] and NMDAR expression 
of GBM cells promotes invasive growth and correlated with poor prognosis [50]. In addition, NMDARs 
and cFos have been suggested as predictive markers for poor prognosis in other cancer types as well 
[49, 53, 99, 101], suggesting that inhibition of NMDAR signaling affects a subpopulation of cells, 
which is highly relevant for therapy. 
The high impact of NMDAR signaling on the clonogenic survival of GBM cells supports this idea. The 
radiosensitizing effect of ifenprodil and Top2β knock-down provides a rationality to inhibit NMDARs 
and Top2β in adjuvant radiotherapy. The explicit role of GluN2B containing NMDARs in migration and 
invasive growths of GBM cells has been reported by others [50, 73, 75]. The radiosensitizing effect as 
well as the prominent reduction of Glu-mediated DSBs and cFos expression by ifenprodil expands the 
impact of GluN2B on GBM cells. Hence, specific targeting of GluN2B containing NMDARs in GBM 
therapy should be considered. Notably, in some countries ifenprodil is an approved drug used to 
prevent brain damage during cerebral infarction or hemorrhage. Ifenprodil has limited side effects and 
clinical trials currently test if ifenprodil might be useful for other applications as well [163, 164]. Thus, 
the use of ifenprodil appears to be a promising way to improve GBM therapy. 
Additionally, Top2 inhibitors are broadly used in cancer treatment and therefore several approved 
drugs with known side effects are available. Most therapeutic strategies which aim at Top2 in cancer 
use Top2 poisons to induce DNA damage and apoptosis [112]. In this line, the targeted activation of 
Top2β-mediated transcription in cancer cells combined with Top2 poisoning has been proposed [117]. 
However, a general disadvantage of Top2 poisons is that the induction of DSBs endangers genomic 
integrity and promotes secondary malignancies [114, 115]. 
   63 
Knock-down of Top2β with siRNA in GBM cells and the resulting radiosensitization demonstrate that 
DSB induction is not needed for a Top2β targeted therapy. Our results indicate that catalytic Top2 
inhibitors like ICRF193 and merbarone, which stop Top2β-mediated transcription, might be useful in 
adjuvant radiotherapy of NMDAR-expressing tumors. The usage of catalytic Top2 inhibitors is thought 
to be less toxic than Top2 poisons and therefore may help to reduce the side effects of cancer therapy 
[110]. 
In summary, the results presented in this thesis confirms the striking role of NMDARs and especially 
the GluN2B subunit on GBM cells and provides rationality to inhibit Top2β-dependent NMDAR 
signaling in cancer therapy. 
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ICRF193 4,4'-(1,2-Dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione 
IDH1   Isocitrate dehydrogenase 1 
Ifenprodil 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol 
iGluR   Ionotropic glutamate-receptor 
Imax   Maximal inducible current 
IR   Ionizing radiation 
Jacob   Juxtasynaptic attractor of caldendrin on dendritic boutons protein 
kDa   Kilo Dalton 
KG501 Naphthol AS-E phosphate 
MAGUK  Membrane-associated guanylate kinases 
Merbarone 5-(N-Phenylcarbamoyl)-2-thiobarbituric acid 
mGluR   Metabotropic glutamate receptor 
MGMT   O6-methylguanine DNA methyltransferase 
Min   Minute 
mRNA   Messenger RNA 
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MWT   Mann-Whitney-Test 
n.s.   not significant 
NBQX   2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline 
NHEJ   Non-homologues end joining 
NMDA   N-Methyl-D-aspartate 
NMDAR  N-Methyl-D-aspartate-receptor 
NSC    Neural stem cell 
NU7441 8-(4-Dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one 
PARP   Poly(ADPribose)polymerase 
PBS   Phosphate-buffered saline 
PFA   Paraformaldehyde 
PI3K   Phosphoinositide-3-kinase 
PolII   DNA dependent RNA polymerase II 
PVDF   Polyvinylidene fluoride 
qPCR   Real-time quantitative PCR 
RNA   Ribonucleic acid 
RT   Room temperature 
SAS   Sulfasalazine 
SDS   Sodium dodecyl sulfate 
Ser   Serine 
siRNA   Small interfering RNA 
TBS   Tris-buffered saline 
TIC   Tumor initiating cell 
TMB   3,3′,5,5′-Tetramethylbenzidin 
TMD    Transmembrane domain 
TMZ   Temozolomide 
Top2   Topoisomerase II 
Top2β   Topoisomerase IIβ 
TORC   Transducer of regulated CREB activity 
Tris   Tris(hydroxymethyl)aminomethane 
TSS   Transcription start site 
Txnip   Thioredoxin-interacting protein 
Tyr   Tyrosine 
WHO   World Health Organization  
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